var title_f26_45_27344="Pulmonary AVM PA";
var content_f26_45_27344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph showing a single, bilobed pulmonary arteriovenous malformation with smooth borders (arrow). There is an area of infiltrate from a recent episode of adult respiratory distress syndrome that lies inferior and lateral to the PAVM.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Gossage, JR, Kanj, G, Am J Respir Crit Care Med 1998; 158:643",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27344=[""].join("\n");
var outline_f26_45_27344=null;
var title_f26_45_27345="Gram stain sputum 6 with answer";
var content_f26_45_27345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Klebsiella pneumoniae in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows plump, beaded, Gram negative rods which suggest a member of the Enterobacteriaceae. Klebsiella pneumoniae grew from this very viscous specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27345=[""].join("\n");
var outline_f26_45_27345=null;
var title_f26_45_27346="Positron emission mammography";
var content_f26_45_27346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Positron emission mammography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Positron emission mammography is a nuclear medicine technique being investigated for the diagnosis of breast cancer.",
"    <br>",
"     (A) Figure A demonstrates normal uptake of the radiolabeled isotope in both breasts.",
"     <br>",
"      (B) Figure B illustrates marked uptake of the isotope in the upper left breast confirming a breast cancer recurrence in a patient who presented with new left supraclavicular lymphadenopathy.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27346=[""].join("\n");
var outline_f26_45_27346=null;
var title_f26_45_27347="Tetracaine (ophthalmic): Drug information";
var content_f26_45_27347=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetracaine (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/36/17987?source=see_link\">",
"    see \"Tetracaine (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/18/13603?source=see_link\">",
"    see \"Tetracaine (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12608998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altacaine;",
"     </li>",
"     <li>",
"      Tetcaine;",
"     </li>",
"     <li>",
"      TetraVisc&trade;;",
"     </li>",
"     <li>",
"      TetraVisc&trade; FORTE",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9564877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pontocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9591281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9565193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Short-term (nonsurgical procedures) anesthesia:",
"     </b>",
"     Ophthalmic: Instill 1-2 drops into affected eye just prior to evaluation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Minor surgical procedures:",
"     </b>",
"     Ophthalmic: Instill 1-2 drops into affected eye every 5-10 minutes for up to 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prolonged surgical procedures:",
"     </b>",
"     Ophthalmic: Instill 1-2 drops into affected eye every 5-10 minutes for up to 5 doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9565194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9565238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 0.5% [5 mg/mL] (2 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altacaine: 0.5% [5 mg/mL] (15 mL, 30 mL) [contains chlorobutanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tetcaine: 0.5% [5 mg/mL] (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TetraVisc&trade;: 0.5% [5 mg/mL) (0.6 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TetraVisc&trade; FORTE: 0.5% [5 mg/mL] (0.6 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9564881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12808748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only; avoid touching tip of applicator to eye, fingers, or other surfaces. Do not use if solution contains crystals, or is cloudy or discolored.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9564898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Local anesthesia for various ophthalmic procedures of short duration (eg, tonometry, gonioscopy); minor ophthalmic surgical procedures (eg, removal of corneal foreign bodies, suture removal); and for various diagnostic purposes (eg, conjunctival scrapings)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9565148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Ocular: Allergic corneal reaction (rare), burning (transient), chemosis, conjunctival redness (transient), lacrimation, photophobia, stinging (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9564903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetracaine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9564904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate type allergic corneal reactions, characterized by epithelial keratitis/filament formation, necrotic epithelium sloughing, stromal edema, descemetitis, and iritis, have been reported rarely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some formulations may contain benzalkonium chloride which may be adsorbed by soft contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; For ophthalmic use only. May delay wound healing. Prolonged use is not recommended. The anesthetized eye should be protected from irritation, foreign bodies, and rubbing to prevent inadvertent damage.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9565151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9564900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9564901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9564902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17917022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tetracaine (ophthalmic) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tetracaine (ophthalmic) to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9565240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Altacaine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (1): $6.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 mL): $10.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tetcaine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 mL): $10.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tetracaine HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (2 mL): $9.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (TetraVisc Forte Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (1): $9.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $30.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (TetraVisc Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (1): $9.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $30.17",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9565181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium, potassium, and other ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9565185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anesthetic: Within 30 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; detoxified by plasma esterases to aminobenzoic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9925 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27347=[""].join("\n");
var outline_f26_45_27347=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608998\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564877\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9591281\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565193\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565194\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565238\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564881\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808748\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564898\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565148\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564903\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564904\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300122\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565151\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564900\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564901\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564902\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917022\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565240\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565181\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565185\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9925\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9925|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/36/17987?source=related_link\">",
"      Tetracaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/18/13603?source=related_link\">",
"      Tetracaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24148?source=related_link\">",
"      Tetracaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/8/38019?source=related_link\">",
"      Tetracaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/8/43138?source=related_link\">",
"      Tetracaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/30/29155?source=related_link\">",
"      Tetracaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/3/25652?source=related_link\">",
"      Tetracaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/31/2547?source=related_link\">",
"      Tetracaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_45_27348="Pityriasis alba 1";
var content_f26_45_27348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60866%7EPC%2F72369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60866%7EPC%2F72369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis alba",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmented macules are present on the face of this young girl with pityriasis alba.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Nicole Sorensen, RN, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Segmental vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segmental vitiligo: patches of hypopigmentation on the anterior trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27348=[""].join("\n");
var outline_f26_45_27348=null;
var title_f26_45_27349="Lateral anatomy of tibia and fibula";
var content_f26_45_27349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Lateral anatomy of tibia and fibula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 591px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27349=[""].join("\n");
var outline_f26_45_27349=null;
var title_f26_45_27350="Light microscopy gonadoblastoma";
var content_f26_45_27350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gonadoblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of an ovarian gonadoblastoma. Cells with small round, dark nuclei resemble immature Sertoli cells and are arrayed around spherical collections of eosinophilic material. Larger seminoma-like cells with clear cytoplasm are scattered about in the lower half of the field. The arrowhead points to a calcification that is typical of this neoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Marisa Nucci, Department of Pathology, Brigham and Womens Hospital, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27350=[""].join("\n");
var outline_f26_45_27350=null;
var title_f26_45_27351="Cystic fibrosis: Clinical manifestations of pulmonary disease";
var content_f26_45_27351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystic fibrosis: Clinical manifestations of pulmonary disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27351/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27351/contributors\">",
"     Julie P Katkin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27351/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27351/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27351/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/45/27351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) is a multisystem disease affecting the digestive system, sweat glands, upper and lower respiratory tracts, and the reproductive tract, but progressive lung disease continues to be the major cause of morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/1\">",
"     1",
"    </a>",
"    ]. CF is characterized by abnormal transport of chloride and sodium across the respiratory epithelium, resulting in thickened, viscous airway secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/2\">",
"     2",
"    </a>",
"    ]. Over a highly variable time course ranging from months to decades after birth, individuals eventually develop chronic infection of the respiratory tract with a characteristic array of bacterial flora [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/3\">",
"     3",
"    </a>",
"    ], leading to progressive respiratory insufficiency and eventual respiratory failure. The rate of progression varies widely, depending in part on genotype (including gene modifiers) as well as environmental factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of CF associated-lung disease is undertaken with a variety of modalities, including mechanical airway clearance, antimicrobials, bronchodilators, supplemental oxygen, mucolytics, and a variety of other novel treatments currently in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32167?source=see_link\">",
"     \"Cystic fibrosis: Investigational therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGRESSION OF PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;CF is caused by mutations in a single large gene on chromosome 7 that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. CFTR has been shown to function as a regulated chloride channel, which in turn may regulate the activity of other chloride and sodium channels at the cell surface. The net result of these changes is an alteration in the rheology of airway secretions, which become thick and difficult to clear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1531054\">",
"    <span class=\"h2\">",
"     Pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic airway obstruction caused by viscous secretions is soon followed by colonization with pathogenic bacteria, including Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa and Burkholderia cepacia complex species. Methicillin resistant Staph aureus is encountered with increasing frequency in many regions. Other organisms frequently encountered in the CF airways include Stenotrophomonas maltophilia, Alcaligenes xylosoxidans and Klebsiella spp., although the contribution of these pathogens to the development of bronchial disease is not always clear. Chronic bacterial infection within the airways occurs in most patients with CF (",
"    <a class=\"graphic graphic_table graphicRef55018 \" href=\"UTD.htm?8/33/8732\">",
"     table 1",
"    </a>",
"    ), and the prevalence of each bacterial type varies with the age of the patient (",
"    <a class=\"graphic graphic_figure graphicRef74073 \" href=\"UTD.htm?18/0/18447\">",
"     figure 1",
"    </a>",
"    ). Even among asymptomatic infants identified by newborn screening, there is evidence of subclinical lung disease within the first few months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/8-10\">",
"     8-10",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Pulmonary function'",
"    </a>",
"    below). Infection with S. Aureus and P. aeruginosa are common even in young children with CF. The presence of P. aeruginosa with a mucoid phenotype is particularly suggestive of CF. Nontuberculous mycobacteria and fungal species such as Aspergillus also contribute to clinical disease in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link&amp;anchor=H2#H2\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Pathogens'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Once infection is established, neutrophils are unable to control the bacteria, even though there is massive infiltration of these inflammatory cells into the lung tissue. Recruited neutrophils subsequently release elastase, which overwhelms the antiproteases of the lung and contributes to tissue destruction. In addition, large amounts of DNA and cytosol matrix proteins are released by degranulating neutrophils, contributing to the increased viscosity of the airway mucus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of patients colonized with Aspergillus develop a hypersensitivity reaction known as allergic bronchopulmonary aspergillosis (ABPA), which causes acute or subacute deterioration of pulmonary function and should be treated. Patients who grow aspergillus species from respiratory cultures but who do not have evidence of ABPA should be observed closely but do not warrant treatment. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Airway reactivity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link&amp;anchor=H24#H24\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Aspergillus species'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1531082\">",
"    <span class=\"h2\">",
"     Bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic inflammation causes lung damage that ultimately advances to the stage of irreversible bronchiectasis and progressive respiratory failure. Terminal findings often include severely congested parenchyma, with grossly purulent secretions in and around dilated airways (",
"    <a class=\"graphic graphic_picture graphicRef59374 \" href=\"UTD.htm?34/49/35601\">",
"     picture 1",
"    </a>",
"    ). The airway epithelium is hyperplastic, often with areas of erosion and squamous metaplasia. Plugs of mucoid material and inflammatory cells are often present in the airway lumen (",
"    <a class=\"graphic graphic_picture graphicRef78974 \" href=\"UTD.htm?29/51/30516\">",
"     picture 2",
"    </a>",
"    ). Submucosal gland hypertrophy and hyperplasia of airway smooth muscle may also be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16057?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of bronchiectasis in children\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory symptoms of CF usually begin early in life, although in milder cases the onset of persistent lung disease may be delayed until the second or third decade [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/1\">",
"     1",
"    </a>",
"    ]. Pulmonary disease is the primary presenting symptom for approximately 40 percent of children diagnosed with CF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Respiratory symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory manifestations of CF usually start with a recurrent cough that gradually becomes persistent. In young infants, this may manifest as prolonged or recurrent episodes of bronchiolitis with tachypnea and wheezing. Eventually, coughing occurs on a daily basis, becoming productive and often paroxysmal. The productive nature of the cough may be overlooked in young children, who tend to swallow sputum.",
"   </p>",
"   <p>",
"    Chronic infection and inflammation lead to progressive tissue damage in the airways. Lysosomal enzymes released from infiltrating neutrophils contribute to progressive destruction of the airway walls. The airways become floppy and collapsible under conditions of high flow, which leads to progressive air trapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/11\">",
"     11",
"    </a>",
"    ]. As the disease progresses, and increase in the anteroposterior diameter of the thorax becomes apparent on physical examination, with many older patients demonstrating a barrel-shaped chest [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/13\">",
"     13",
"    </a>",
"    ]. Other late complications include spontaneous pneumothorax and hemoptysis, which may be massive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H32#H32\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Noninfectious pulmonary complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Airway reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway hyperreactivity is a common finding in CF patients. In one study of young children with CF (mean age 16 months), 50 percent had wheezing, and 43 percent of children who wheezed were responsive to bronchodilator therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/16\">",
"     16",
"    </a>",
"    ]. Many patients continue to demonstrate bronchial hyperresponsiveness into adolescence and adulthood, with positive correlations between the degree of airway reactivity and overall severity of lung disease. Although invasive fungal disease is rare in patients with CF, allergic bronchopulmonary aspergillosis (ABPA) is increasingly recognized in CF patients. Marked exacerbation of wheezing or otherwise unexplained deterioration in lung function despite antibiotic therapy in CF patients should prompt a careful evaluation for this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, patients with CF sometimes become less responsive to bronchodilators over time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/3\">",
"     3",
"    </a>",
"    ]. This phenomenon may occur when progressive airway damage leads to a loss of cartilaginous support, resulting in an increased reliance on muscle tone for maintenance of airway patency. In this setting, the muscle relaxation caused by bronchodilators can cause collapse of such \"floppy\" airways, leading to increased airflow obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with mild lung disease, the chest radiograph may appear normal for many years, but in most patients at least mild radiographic findings are evident in the first decade of life. The first discernible change is usually hyperinflation, which may initially be reversible with treatment for acute exacerbations of infection. As the disease progresses, hyperinflation becomes persistent, and the bronchovascular markings become more prominent. For unclear reasons, abnormalities tend to appear in the upper lobes first, progressing to the lower lobes with advancing disease.",
"   </p>",
"   <p>",
"    With time, the bronchovascular markings progress to a pattern of bronchiectasis and cyst formation. Peribronchial cuffing and \"tram tracks\" (parallel lines caused by thickened bronchial walls in longitudinal section) appear, followed by the rounded shadows of saccular bronchiectasis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56034 \" href=\"UTD.htm?14/19/14655\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=see_link\">",
"     \"Clinical manifestations and evaluation of bronchiectasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increasing hyperinflation leads to progressive flattening of the diaphragms, a prominent retrosternal space, and kyphosis in late stages of disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71098 graphicRef55878 \" href=\"UTD.htm?39/50/40745\">",
"     image 2A-B",
"    </a>",
"    ). Thin-walled cysts (most common in the upper lobes) may appear to extend to the lung surface, and pneumothorax is observed with increasing frequency in older patients. In advanced stages of disease, the chest radiograph may demonstrate little or no correlation with acute clinical changes.",
"   </p>",
"   <p>",
"    With good clinical care and careful attention to daily airway clearance, the classic radiographic signs of CF may be delayed for many years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chest computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) of the chest may be helpful in defining the extent of bronchiectasis in some patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53471 \" href=\"UTD.htm?10/43/10930\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/17\">",
"     17",
"    </a>",
"    ]. This is of particular interest in patients who have focal areas of advanced disease, which may sometimes be amenable to surgical resection. CT surveillance may also be useful to monitor the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of disease caused by atypical mycobacteria.",
"   </p>",
"   <p>",
"    The degree of bronchiectasis noted on CT is associated with infection with mucoid strains of Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the degree of bronchiectasis is only weakly correlated with measures of pulmonary function, and not well correlated with exercise performance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Serial high resolution CT scans often display progressively severe disease, despite apparently stable pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Thus, changes in pulmonary function may be more subtle than or lag behind the CT abnormalities. CT scanning may demonstrate evidence of unsuspected air trapping and inhomogeneities of lung inflation even in very young asymptomatic children, and are thus a sensitive indicator of early disease in children too young to perform pulmonary function testing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/23\">",
"     23",
"    </a>",
"    ]. More studies will be needed to determine the role of serial CT scanning in the evaluation and care of CF patients, balancing the risk of repeated exposure to radiation with the potential benefits of earlier identification of bronchiectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contrast bronchography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the advent of CT scanning, there is no clinical indication for contrast bronchography. When they were used in the past, they often provided evidence of saccular bronchiectasis in patients with advanced CF (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61165 \" href=\"UTD.htm?2/38/2660\">",
"     image 4",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PULMONARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with CF, subtle changes in lung structure and function may be identifiable from a very early age, even before clinical signs of disease are apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Pulmonary function tests (PFT) in infants are performed using a technique of forced expiration and are well validated. In infants with CF, the tests typically are normal at the time of diagnosis by newborn screening, but may deteriorate by six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/27\">",
"     27",
"    </a>",
"    ]. The decline in infant pulmonary function is associated with signs of pulmonary inflammation and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/10\">",
"     10",
"    </a>",
"    ]. Infant lung function tests have been shown to correlate with results of standard pulmonary function testing performed six years later [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Over time, the majority of CF patients develop an obstructive pattern on PFT. The most sensitive measures of early airway obstruction are increases in the ratio of residual volume to total lung capacity",
"    <span class=\"nowrap\">",
"     (RV/TLC)",
"    </span>",
"    and decreases in the forced expiratory flow at 25 to 75 percent of lung volume (FEF25-75 percent). As disease progresses, spirometry reveals a decline in the forced expiratory volume in one second (FEV1) and the ratio of FEV1 to forced vital capacity",
"    <span class=\"nowrap\">",
"     (FEV1/FVC)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung volumes demonstrate increases in total lung capacity (TLC) and residual volume (RV) as hyperinflation progresses. Helium may diffuse very slowly into congested areas of the lung, so the helium diffusion technique may underestimate these parameters. Plethysmography provides a more accurate measure of lung volumes in patients with CF, and a comparison of volumes obtained by the two techniques may provide a quantitative measure of underventilated lung volume.",
"   </p>",
"   <p>",
"    A technique of multiple-breath inert gas washout has been employed to detect early lung disease in infants and young children with CF. This technique appears to have greater sensitivity to detect early airway obstruction as compared to spirometry, and may have future research applications in evaluating new therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CF patients demonstrate greater within-patient variability in pulmonary function than do normal subjects, even with extensive practice in performance of the maneuvers. These variations reflect fluctuations in the degree of airway inflammation, so PFTs are reliable indicators of acute changes in respiratory function. As an example, the FEV1 and FVC may drop 10 to 15 percent with acute exacerbations and return to \"baseline\" values after several weeks of treatment. These fluctuations are often used as indicators for the adequacy of treatment during acute flares of bronchitis.",
"   </p>",
"   <p>",
"    Despite intensive therapy, pulmonary function gradually decreases as patients get older, although the pattern of change is unpredictable and varies greatly among individuals. The patterns that may be seen include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Linear decreases in FVC and FEV1",
"     </li>",
"     <li>",
"      Near normal pulmonary function for many years, followed by a rapid decline",
"     </li>",
"     <li>",
"      Stepwise decreases in measurements of pulmonary function, separated by years of stability at a new level of function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The FEV1 is correlated with survival in CF patients. In a large observational study, predictors of the rate of decline in FEV1 included poor nutritional status, Pseudomonas aeruginosa infection, persistent crackles on examination, and frequency of pulmonary exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/31\">",
"     31",
"    </a>",
"    ]. Surprisingly, high baseline FEV1 also predicted a faster rate of decline, suggesting that clinicians should not be reassured by apparently high lung function, particularly in younger children. A rapid decline in FEV1, or an FEV1 persistently lower than 30 percent of predicted may be useful indicators of the need for transplant evaluation in patients with CF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H26#H26\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Lung transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GAS EXCHANGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As bronchiectasis and airway obstruction become more pronounced, ventilation-perfusion mismatch leads to hypoxemia. This may initially occur only during sleep or exercise, but patients with advanced disease often require continuous oxygen supplementation. Hypercapnia occurs relatively late in the course of CF lung disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic hypoxemia and hypercarbia may lead to muscular hypertrophy of the pulmonary vasculature, right ventricular hypertrophy, and eventually cor pulmonale with right heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polycythemia is typically occurs in patients with congenital heart disease as a physiologic compensation for chronic hypoxia. By contrast, polycythemia is a rare finding in CF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27351/abstract/11\">",
"     11",
"    </a>",
"    ]. Several factors may prevent the polycythemic response in patients with CF, including the anemia of chronic disease and iron deficiency. In addition, blood volume tends to increase as the disease progresses, so absolute increases in red cell mass may not be reflected in the hematocrit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=see_link\">",
"       \"Patient information: Cystic fibrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16847652\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cystic fibrosis (CF) have chronic airway obstruction caused by viscous respiratory secretions. This predisposes them to chronic pulmonary infection with pathogenic bacteria, including Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa, and Burkholderia cepacia complex species (",
"      <a class=\"graphic graphic_table graphicRef55018 \" href=\"UTD.htm?8/33/8732\">",
"       table 1",
"      </a>",
"      ); the prevalence of each bacterial type varies with the age of the patient (",
"      <a class=\"graphic graphic_figure graphicRef74073 \" href=\"UTD.htm?18/0/18447\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1531054\">",
"       'Pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic inflammation causes lung damage that ultimately advances to the stage of irreversible bronchiectasis and progressive respiratory failure. Terminal findings often include severely congested parenchyma, with grossly purulent secretions in and around dilated airways (",
"      <a class=\"graphic graphic_picture graphicRef59374 \" href=\"UTD.htm?34/49/35601\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1531082\">",
"       'Bronchiectasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory manifestations of CF usually start with a recurrent cough that gradually becomes persistent. In young infants, this may manifest as prolonged or recurrent episodes of bronchiolitis with tachypnea and wheezing. Eventually, coughing occurs on a daily basis, becoming productive and often paroxysmal. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Respiratory symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airway hyperreactivity is a common finding in CF patients, manifested by wheezing which is initially responsive to bronchodilator therapy. However, as the disease progresses the airway tends to become floppier and patients may become unresponsive to bronchodilator administration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Airway reactivity'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The chest radiograph may appear normal for the first few years of life, or longer in patients with mild disease. The first discernible change is usually hyperinflation. Later, bronchovascular markings become more prominent. In advanced disease, the chest radiograph reveals peribronchial cuffing and \"tram tracks,\" followed by the rounded shadows of saccular bronchiectasis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56034 \" href=\"UTD.htm?14/19/14655\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Plain films'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-resolution computed tomography (HRCT) is a sensitive measure of CF lung disease. Serial HRCT scans may detect progressive disease before changes are noted in pulmonary function tests (PFTs) or clinical symptoms. The clinical utility of HRCT in making management decisions has not been established. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chest computed tomography'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      CF is characterized by the following findings on PFTs (in the order in which the abnormalities develop as the disease progresses) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Pulmonary function'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increases in the ratio of residual volume to total lung capacity",
"      <span class=\"nowrap\">",
"       (RV/TLC)",
"      </span>",
"     </li>",
"     <li>",
"      Decreases in the forced expiratory flow at 25 to 75 percent of lung volume (FEF25-75 percent)",
"     </li>",
"     <li>",
"      Decline in the forced expiratory volume in one second (FEV1) and the ratio of FEV1 to forced vital capacity",
"      <span class=\"nowrap\">",
"       (FEV1/FVC)",
"      </span>",
"     </li>",
"     <li>",
"      Increases in total lung capacity (TLC) and residual volume (RV), which are most accurately measured by plethysmography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The results of PFTs vary with acute changes in respiratory function. In addition, patients exhibit an overall declining trend in pulmonary function as their disease progresses, but the decline may not be linear. Decline in FEV1 is associated with diminished survival. A rapid decline in FEV1 or an FEV1 persistently lower than 30 percent of predicted are useful indicators of the need for transplant evaluation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pulmonary function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/1\">",
"      Ratjen F, D&ouml;ring G. Cystic fibrosis. Lancet 2003; 361:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/2\">",
"      Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/3\">",
"      Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/4\">",
"      Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/5\">",
"      Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/6\">",
"      Drumm ML, Collins FS. Molecular biology of cystic fibrosis. Mol Genet Med 1993; 3:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/7\">",
"      Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest 1999; 103:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/8\">",
"      Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/9\">",
"      Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009; 155:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/10\">",
"      Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184:75.",
"     </a>",
"    </li>",
"    <li>",
"     Davis, PB. Pathophysiology of the lung disease in cystic fibrosis. In: Cystic Fibrosis, Davis, PB (Ed), Marcel Dekker, New York 1993. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/12\">",
"      Hays SR, Ferrando RE, Carter R, et al. Structural changes to airway smooth muscle in cystic fibrosis. Thorax 2005; 60:226.",
"     </a>",
"    </li>",
"    <li>",
"     Taussig, LM. Cystic fibrosis: An overview. In: Cystic Fibrosis, Taussig, LM (Ed), Thieme-Stratton, New York 1984. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/14\">",
"      Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/15\">",
"      Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/16\">",
"      Hiatt P, Eigen H, Yu P, Tepper RS. Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis 1988; 137:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/17\">",
"      de Jong PA, Ottink MD, Robben SG, et al. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004; 231:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/18\">",
"      Farrell PM, Collins J, Broderick LS, et al. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology 2009; 252:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/19\">",
"      Edwards EA, Narang I, Li A, et al. HRCT lung abnormalities are not a surrogate for exercise limitation in bronchiectasis. Eur Respir J 2004; 24:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/20\">",
"      de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004; 23:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/21\">",
"      Cademartiri F, Luccichenti G, Palumbo AA, et al. Predictive value of chest CT in patients with cystic fibrosis: a single-center 10-year experience. AJR Am J Roentgenol 2008; 190:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/22\">",
"      de Jong PA, Tiddens HA. Cystic fibrosis specific computed tomography scoring. Proc Am Thorac Soc 2007; 4:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/23\">",
"      Brody AS, Tiddens HA, Castile RG, et al. Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med 2005; 172:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/24\">",
"      Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004; 144:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/25\">",
"      Castile RG, Iram D, McCoy KS. Gas trapping in normal infants and in infants with cystic fibrosis. Pediatr Pulmonol 2004; 37:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/26\">",
"      Belessis Y, Dixon B, Hawkins G, et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. Am J Respir Crit Care Med 2012; 185:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/27\">",
"      Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008; 178:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/28\">",
"      Harrison AN, Regelmann WE, Zirbes JM, Milla CE. Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/29\">",
"      Aurora P, Gustafsson P, Bush A, et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax 2004; 59:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/30\">",
"      Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008; 63:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/31\">",
"      Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27351/abstract/32\">",
"      Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6369 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27351=[""].join("\n");
var outline_f26_45_27351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16847652\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGRESSION OF PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1531054\">",
"      Pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1531082\">",
"      Bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Respiratory symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Airway reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Plain films",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chest computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contrast bronchography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PULMONARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GAS EXCHANGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16847652\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6369\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6369|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/19/14655\" title=\"diagnostic image 1\">",
"      CXR bronchiect child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/48/12036\" title=\"diagnostic image 2A\">",
"      Cystic fibrosis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/31/33270\" title=\"diagnostic image 2B\">",
"      Adult cystic fibrosis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/43/10930\" title=\"diagnostic image 3\">",
"      Bronchiectasis CF CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/38/2660\" title=\"diagnostic image 4\">",
"      Bronchiectasis CF PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6369|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/0/18447\" title=\"figure 1\">",
"      CF colonization by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6369|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/49/35601\" title=\"picture 1\">",
"      Cystic fibrosis lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/51/30516\" title=\"picture 2\">",
"      Cystic fibrosis light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6369|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/33/8732\" title=\"table 1\">",
"      CF microorganisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16057?source=related_link\">",
"      Causes of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=related_link\">",
"      Clinical manifestations and evaluation of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32167?source=related_link\">",
"      Cystic fibrosis: Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_45_27352="Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis";
var content_f26_45_27352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27352/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27352/contributors\">",
"     Paul Ciechanowski, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27352/contributors\">",
"     Wayne Katon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27352/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27352/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/45/27352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttraumatic stress disorder (PTSD) has been described as \"the complex somatic, cognitive, affective and behavioral effects of psychological trauma\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/1\">",
"     1",
"    </a>",
"    ]. PTSD is characterized by intrusive thoughts, nightmares and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.",
"   </p>",
"   <p>",
"    The diagnosis of PTSD can be challenging because of the heterogeneity of the presentation and resistance on the part of the patient to discuss past trauma.",
"   </p>",
"   <p>",
"    The diagnosis of PTSD is made in the subset of people who have experienced trauma who are unable to cope with the consequences of trauma and whose well-being over time is greatly impacted by these consequences. Concerns have been expressed about the potential to \"over-medicalize\" normal reactions to trauma, on one hand, while failing to recognize and address PTSD, on the other [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacotherapy and psychotherapy of PTSD are discussed separately. The epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of PTSD with dissociative features are also discussed separately. The epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of acute stress disorder are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=see_link\">",
"     \"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=see_link\">",
"     \"Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=see_link\">",
"     \"Treatment of acute stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different types of trauma have been found to result in PTSD, including those listed below. Many of these events are common, resulting in a large number of affected individuals.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Military combat",
"     </li>",
"     <li>",
"      Violent personal assault",
"     </li>",
"     <li>",
"      Natural and man-made disasters",
"     </li>",
"     <li>",
"      Severe motor vehicle accidents",
"     </li>",
"     <li>",
"      Rape",
"     </li>",
"     <li>",
"      Incest",
"     </li>",
"     <li>",
"      Childhood sexual abuse",
"     </li>",
"     <li>",
"      Diagnosis of a life-threatening illness",
"     </li>",
"     <li>",
"      Severe physical injury",
"     </li>",
"     <li>",
"      Hospitalization in an intensive care unit (ICU)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence and susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime prevalence of PTSD ranges from 6.8 to 12.3 percent in the general adult population in the United States (US) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], with one-year prevalence rates of 3.5 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. In a study of 368 patients from a community primary care clinic, 65 percent reported a history of exposure to severe, potentially traumatic events; 12 percent went on to develop PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Personal and societal factors appear to affect both the likelihood of developing PTSD after a traumatic event and the clinical presentation of PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Risk factors for PTSD include lower socioeconomic status, parental neglect, family or personal history of a psychiatric condition, poor social support, and initial severity of reaction to the traumatic event [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In a study of male patients treated in primary care, Veterans Administration (VA) practices, 36 percent of patients who had been diagnosed with major depression screened positive for PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trauma exposure and PTSD have also been associated with physical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/14\">",
"     14",
"    </a>",
"    ]. In a population-based study of 3171 community respondents, PTSD was associated with increased risks for angina (OR 2.4, 95% CI 1.3, 4.5), heart failure (OR 3.4, 95% CI 1.9, 6.0), bronchitis, asthma, liver, and peripheral artery disease (ORs range = 2.5, 3.1) after adjusting for sociodemographic factors, smoking, body mass index, blood pressure, depression, and alcohol use disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which PTSD occurs after a traumatic event is influenced by characteristics of the individual and the inciting event [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/15\">",
"     15",
"    </a>",
"    ]. Overall, women are four times more likely to develop PTSD than men, after adjusting for exposure to traumatic events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/10\">",
"     10",
"    </a>",
"    ]. The rates of PTSD are similar among men and women after events such as accidents (6.3 versus 8.8 percent), natural disasters (3.7 versus 5.4 percent), or sudden death of a loved one (12.6 versus 16.2 percent). Although women are more than 10 times as likely as men to be raped, the incidence of PTSD after rape is higher in men (65 versus 46 percent). The rate of PTSD is lower in men than in women after events such as molestation (12.2 versus 26.5 percent) and physical assault (1.8 versus 21.3 percent).",
"   </p>",
"   <p>",
"    Higher rates of PTSD have been found in subgroups in the US compared to the general population, including Native Americans living on reservations and refugees from countries where traumatic stress was endemic. In two large samples of Native Americans, lifetime prevalence of PTSD ranged from 14.2 to 16.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/16\">",
"     16",
"    </a>",
"    ]. Among Cambodian refugees two decades after resettling in the US, 62 percent met criteria for PTSD in the last year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Sexual assault",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual assault is the most frequent type of trauma experienced by women with PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. In a nationally representative sample of 4,008 women in the United States (US), the lifetime prevalence of PTSD was 12.3 percent. Of the women who had a history of PTSD, 32 percent had been raped and 31 percent experienced a sexual assault other than rape [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mass conflict and displacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 145 studies of 64,332 refugees and other conflict-affected individuals internationally found a mean PTSD prevalence rate of 30.6 percent (95% CI, 26.3 - 35.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/19\">",
"     19",
"    </a>",
"    ]. Factors associated with higher PTSD rates included reported torture, cumulative exposure to potentially traumatic events, shorter time since conflict, and the assessed level of political terror.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Combat",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTSD occurring after combat injury appears to be strongly correlated with the extent of injury, and develops over several months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/20\">",
"     20",
"    </a>",
"    ]. Rates of a positive screen for PTSD were higher when US veterans were surveyed three to six months following return from active duty, compared to results of surveys immediately on return [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, up to 60 percent of returning soldiers with a positive PTSD screen on their initial survey reported symptom improvement by three to six months.",
"   </p>",
"   <p>",
"    In another study of US soldiers hospitalized for war-related injuries, the prevalence of PTSD was 4.2 percent at one month and 12.2 percent by four months post-injury. Soldiers with a high severity of physical problems a month after injury were at greater risk of PTSD six months later, compared to those with lower physical problem severity (OR 7.0, 95% CI 3.1-16.0). Almost one-half of soldiers with war-related mild traumatic brain injury (concussion syndrome) met criteria for PTSD in one study; ongoing symptoms that had been attributed to direct effects of the brain injury may in fact relate to PTSD and be amenable to appropriate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    War-related PTSD has been associated with long-term consequences for mental health [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/23\">",
"     23",
"    </a>",
"    ]. A longitudinal cohort study compared a random sample of 450 Australian Vietnam veterans with matched subjects from the Australian general population. When assessed 36 years after the war, veterans with war-related PTSD were more likely than members of the general population to have depression, an anxiety disorder (eg, social phobia, panic disorder, agoraphobia with or without panic disorder, and specific blood phobia), alcohol dependence, or persistent pain disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     ICU hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic analysis of 15 studies found the prevalence of PTSD in patients who survived intensive care unit (ICU) hospitalization to be approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/24\">",
"     24",
"    </a>",
"    ]. Predictors of PTSD included prior psychopathology and greater use of benzodiazepines in the ICU; severity of critical illness was not a predictor of PTSD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link\">",
"     \"Overview of inpatient management in the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15162345\">",
"    <span class=\"h3\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 24 observational studies including 2383 patients who experienced an acute coronary syndrome (ACS; ie, a myocardial infarction or unstable angina) found a prevalence rate of ACS-induced PTSD of 12 percent (95% CI 9-16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/25\">",
"     25",
"    </a>",
"    ]. Data from three studies of 609 patients that met quality criteria for the meta-analysis showed found that patients experiencing ACS-induced PTSD had a two-fold risk of subsequent mortality or ACS recurrence (risk ratio = 2; 95% CI 1.69&ndash;2.37) compared to ACS patients who did not experience PTSD symptoms. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=see_link\">",
"     \"Overview of the non-acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive analyses of the cost of PTSD are rare, but suggest that PTSD is associated with increased health care costs and other direct and indirect costs. One study that looked at women with PTSD in a health maintenance organization (HMO) found that compared with women with few symptoms of PTSD, women with moderate and severe PTSD symptoms had increased median annual health care costs (38 and 104 percent higher, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/26\">",
"     26",
"    </a>",
"    ]. Exposure to trauma itself appears to be extremely costly in terms of the impact upon victims and their families and upon society. In one study, for example, severely victimized women in an HMO setting had medical expenses twice that of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/27\">",
"     27",
"    </a>",
"    ]. Other reports have estimated direct annual costs of personal crime in the US nationally to be $105 billion (medical costs, lost earnings, victim assistance programs); that figure increases to $450 billion annually when intangible losses (pain, suffering, quality of life) are considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While much of the pathophysiology of PTSD is unclear, interesting research findings are accruing. Studies using MRI scans have shown that there is decreased volume of the hippocampus, left amygdala, and anterior cingulate cortex in patients with PTSD compared with matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Other reports have demonstrated increased central norepinephrine levels with down-regulated central adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/31\">",
"     31",
"    </a>",
"    ], chronically decreased glucocorticoid levels with up-regulation of their receptors (possibly accounting for the anecdotal finding that there are more autoimmune diseases in these patients), and hemispheric lateralization in which there is a relative failure of left hemispheric function (possibly accounting for confusion related to time sequence of traumatic events) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Researchers suspect that genetics may contribute to an individual's susceptibility to PTSD through an interaction with environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/33\">",
"     33",
"    </a>",
"    ]. However, research studies on the genetics of PTSD have generally been small and findings have been inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/34\">",
"     34",
"    </a>",
"    ]. As an example of a potential gene-environment interaction, the presence of one of four polymorphisms at the stress-related gene FKBP5 was found to be associated with an increased risk for PTSD in patients with a history of child abuse, but not in patients without history of child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previous exposure to trauma appears to increase the risk of developing PTSD with subsequent traumatic events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/36\">",
"     36",
"    </a>",
"    ]. The mechanism by which this \"sensitization\" occurs is unclear. A study of severely injured accident victims who were healthy before experiencing trauma found that the incidence of PTSD was low [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals who experience trauma react to some degree when experiencing reminders of the trauma. Patients with PTSD, however, experience marked cognitive, affective, and behavioral responses to stimuli, leading to flashbacks, severe anxiety, and fleeing or combative behavior. These individuals compensate for such intense arousal by attempting to avoid experiences that may begin to elicit symptoms; this can result in emotional numbing, diminished interest in everyday activities and, in the extreme, may result in detachment from others.",
"   </p>",
"   <p>",
"    There are important distinguishing characteristics of PTSD symptoms in patients who experienced most of their trauma in childhood (eg, physical and sexual abuse) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/1\">",
"     1",
"    </a>",
"    ]. Compared with controls, these individuals often show greater difficulty with affect regulation (eg, unmodulated anger), and often demonstrate more dissociation, somatization, self-destructive behavior, and suicidal behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Co-occurring conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric comorbidity is high in patients with PTSD. The National Comorbidity Survey data suggests that 16 percent have one coexisting psychiatric disorder, 17 percent have two psychiatric disorders, and 50 percent have three or more [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/4\">",
"     4",
"    </a>",
"    ]. Depressive disorders, anxiety disorders, and substance abuse are two to four times more prevalent in patients with PTSD; substance abuse is often due to the patient's attempts to self-medicate symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traumatic brain injury (TBI) and PTSD have high rates of co-occurrence among civilians and, particularly, among soldiers who suffer combat-related TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/38\">",
"     38",
"    </a>",
"    ]. As an example, 11 percent of American soldiers returning from combat in Iraq and Afghanistan were reported to screen positive for PTSD in 2008. Among returning soldiers with mild TBI, 62 percent screened positive for PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies suggest that somatization disorder is as much as 90 times more likely in patients with PTSD than in patients without the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals who develop PTSD experience its onset within a few months of the traumatic event. However, epidemiologic studies have found that approximately 25 percent experience a delayed onset after six months or more [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTSD is commonly a chronic condition with only one-third of patients recovering at one year follow-up, and one-third still symptomatic ten years after the exposure to the trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/4\">",
"     4",
"    </a>",
"    ]. Individuals with one or more PTSD symptoms are more likely to experience occupational problems, have poorer social supports, and have more disability than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/42\">",
"     42",
"    </a>",
"    ]. PTSD may increase the risk for attempted suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Individuals with PTSD have higher rates of problems in intimate relationships, including marital difficulties, compared to people without PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/42,45\">",
"     42,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individual psychotherapy has been found to improve overall psychosocial functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/46\">",
"     46",
"    </a>",
"    ]. Accumulating evidence suggests that cognitive-behavioral conjoint therapy for individuals with PTSD and their partners is an effective strategy for reducing PTSD symptom severity and increasing intimate relationship satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link&amp;anchor=H324030410#H324030410\">",
"     \"Psychotherapy for posttraumatic stress disorder\", section on 'Couples therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with symptoms of PTSD should receive a comprehensive psychiatric assessment. A diagnosis of PTSD is made for patients who meet all of the criteria below from the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR); (",
"    <a class=\"graphic graphic_table graphicRef57500 \" href=\"UTD.htm?8/55/9085\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A severe, traumatic event causing intense fear or helplessness",
"     </li>",
"     <li>",
"      Resulting symptoms in each of three categories",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reexperiencing",
"     </li>",
"     <li>",
"      Avoidance",
"     </li>",
"     <li>",
"      Arousal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Social or occupational impairment",
"     </li>",
"     <li>",
"      Symptoms and functional impairment lasting more than one month after the trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of questions a clinician can ask to elicit symptoms are provided below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How do you feel when you recall the event?",
"     </li>",
"     <li>",
"      Do you experience dreams or flashbacks about it?",
"     </li>",
"     <li>",
"      Do you find yourself avoiding people or activities you associate with the event?",
"     </li>",
"     <li>",
"      Do you find yourself forgetting occurrences from that period?",
"     </li>",
"     <li>",
"      Do you find yourself looking carefully around when you are in a public place?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients need to be asked specific questions about their traumatic experience(s) to differentiate PTSD from other psychiatric disorders. These questions should be asked with sensitivity. Patients are often reluctant to discuss past traumatic events because of guilt, embarrassment, or discomfort inherent in revisiting painful memories.",
"   </p>",
"   <p>",
"    Patients may minimize their symptoms of PTSD. Some patients may feel that past trauma has little or no effect on present symptoms. Military personnel in the US have been reported to be reluctant to disclose PTSD symptoms due to stigmatization and fear of professional repercussions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients diagnosed with PTSD should also be assessed for suicidal or parasuicidal ideation or acts and co-occurring psychiatric conditions, substance use disorders, and medical conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Instruments for screening and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In screening patients for PTSD, eg, primary care patients, returning veterans, or individuals experiencing domestic violence, particular attention should be paid to individuals presenting with new anxiety, fear, or insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/50\">",
"     50",
"    </a>",
"    ]. Furthermore, clinicians may want to pay attention to associated behaviors in individuals at risk for PTSD anxiety symptoms, such as social isolation, increased substance abuse (alcohol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tobacco), or attempts at distraction through excessive work.",
"   </p>",
"   <p>",
"    The PTSD checklist (PCL) may be helpful in screening patients for PTSD and monitoring the progress of treatment over time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/51\">",
"     51",
"    </a>",
"    ]. Versions of this tool have been developed for civilian and military populations (",
"    <a class=\"graphic graphic_form graphicRef51518 \" href=\"UTD.htm?16/39/17013\">",
"     form 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_form graphicRef65285 \" href=\"UTD.htm?13/7/13429\">",
"     form 2",
"    </a>",
"    ). For differing populations, the sensitivity of the PCL ranges from .69 to .94 and the specificity is from .83 to .99 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. A score of 50 out of a maximum score of 85 is associated with a diagnosis of PTSD. While the PCL is self-administered by patients, another option for assessing severity is the Clinician-Administered PTSD Scale (CAPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27352/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Differentiating acute stress disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals presenting with symptoms of post-traumatic stress and functional impairment after a highly traumatic event are diagnosed as having acute stress disorder (ASD) for the first 30 days following the event. &nbsp;Most people recover completely within this period. &nbsp;For those who remain symptomatic (at the threshold established by DSM-IV-TR criteria), their diagnosis is then reclassified as PTSD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/45/8914?source=see_link\">",
"       \"Patient information: Post-traumatic stress disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The one-year prevalence of PTSD ranges from 3.5 to 6 percent in the US general adult population. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many different types of trauma can result in PTSD, including military combat, sexual or physical assault, disasters, childhood sexual abuse, severe physical injury, and ICU hospitalization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology of PTSD is not well understood. However, differences in neuroanatomy, neurotransmitters, and brain functioning have been found in individuals with the disorder. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with PTSD experience marked cognitive, affective, and behavioral responses to stimuli reminding them of trauma they experienced, eg, flashbacks, severe anxiety, and fleeing or combative behavior. They compensate for this intense arousal through avoidance, emotional numbing, and diminished interest in people and activities. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PTSD is commonly accompanied by comorbid psychiatric conditions, including depression, substance use disorders, and somatization. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Co-occurring conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic criteria for PTSD include: experiencing a severe, traumatic event causing intense fear; resulting symptoms in each of three categories (reexperiencing trauma, avoiding trauma-associated stimuli, and increased arousal); social or occupational impairment; and symptoms and impairment lasting at least one month after the trauma (",
"      <a class=\"graphic graphic_table graphicRef57500 \" href=\"UTD.htm?8/55/9085\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diagnosis of PTSD is made only after a month has passed since the traumatic event. Prior to that time, patients with PTSD-like symptoms and functional impairment are diagnosed with acute stress disorder. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/1\">",
"      van der Kolk BA, Pelcovitz D, Roth S, et al. Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. Am J Psychiatry 1996; 153:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/2\">",
"      Stein DJ, Seedat S, Iversen A, Wessely S. Post-traumatic stress disorder: medicine and politics. Lancet 2007; 369:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/3\">",
"      Resnick HS, Kilpatrick DG, Dansky BS, et al. Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J Consult Clin Psychol 1993; 61:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/4\">",
"      Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/5\">",
"      Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/6\">",
"      Norris FH. Epidemiology of trauma: frequency and impact of different potentially traumatic events on different demographic groups. J Consult Clin Psychol 1992; 60:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/7\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/8\">",
"      Stein MB, McQuaid JR, Pedrelli P, et al. Posttraumatic stress disorder in the primary care medical setting. Gen Hosp Psychiatry 2000; 22:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/9\">",
"      Kroll J. Posttraumatic symptoms and the complexity of responses to trauma. JAMA 2003; 290:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/10\">",
"      Vieweg WV, Julius DA, Fernandez A, et al. Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. Am J Med 2006; 119:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/11\">",
"      Liebschutz J, Saitz R, Brower V, et al. PTSD in urban primary care: high prevalence and low physician recognition. J Gen Intern Med 2007; 22:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/12\">",
"      Bisson JI. Post-traumatic stress disorder. BMJ 2007; 334:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/13\">",
"      Campbell DG, Felker BL, Liu CF, et al. Prevalence of depression-PTSD comorbidity: implications for clinical practice guidelines and primary care-based interventions. J Gen Intern Med 2007; 22:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/14\">",
"      Spitzer C, Barnow S, V&ouml;lzke H, et al. Trauma, posttraumatic stress disorder, and physical illness: findings from the general population. Psychosom Med 2009; 71:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/15\">",
"      Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002; 346:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/16\">",
"      Beals J, Manson SM, Whitesell NR, et al. Prevalence of DSM-IV disorders and attendant help-seeking in 2 American Indian reservation populations. Arch Gen Psychiatry 2005; 62:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/17\">",
"      G. N. Marshall, T. L. Schell, M. N. Elliott, S. M. Berthold, and C. A. Chun. Mental health of Cambodian refugees 2 decades after resettlement in the United States. JAMA 2005; 294:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/18\">",
"      Chivers-Wilson KA. Sexual assault and posttraumatic stress disorder: a review of the biological, psychological and sociological factors and treatments. Mcgill J Med 2006; 9:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/19\">",
"      Steel Z, Chey T, Silove D, et al. Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. JAMA 2009; 302:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/20\">",
"      Grieger TA, Cozza SJ, Ursano RJ, et al. Posttraumatic stress disorder and depression in battle-injured soldiers. Am J Psychiatry 2006; 163:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/21\">",
"      Milliken CS, Auchterlonie JL, Hoge CW. Longitudinal assessment of mental health problems among active and reserve component soldiers returning from the Iraq war. JAMA 2007; 298:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/22\">",
"      Hoge CW, McGurk D, Thomas JL, et al. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med 2008; 358:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/23\">",
"      O'Toole BI, Catts SV, Outram S, et al. The physical and mental health of Australian Vietnam veterans 3 decades after the war and its relation to military service, combat, and post-traumatic stress disorder. Am J Epidemiol 2009; 170:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/24\">",
"      Davydow DS, Gifford JM, Desai SV, et al. Posttraumatic stress disorder in general intensive care unit survivors: a systematic review. Gen Hosp Psychiatry 2008; 30:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/25\">",
"      Edmondson D, Richardson S, Falzon L, et al. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: a meta-analytic review. PLoS One 2012; 7:e38915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/26\">",
"      Walker EA, Katon W, Russo J, et al. Health care costs associated with posttraumatic stress disorder symptoms in women. Arch Gen Psychiatry 2003; 60:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/27\">",
"      Koss MP, Woodruff WJ, Koss PG. Criminal victimization among primary care medical patients: prevalence, incidence, and physician usage. Behav Sci Law 1991; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, TR, Cohen, MA, Wiersma, B. Victim costs and consequences: A new look. United States Department of Justice, National Institute of Justice, Research Report, Washington, DC 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/29\">",
"      Bremner JD, Randall P, Scott TM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 1995; 152:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/30\">",
"      Karl A, Schaefer M, Malta LS, et al. A meta-analysis of structural brain abnormalities in PTSD. Neurosci Biobehav Rev 2006; 30:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/31\">",
"      Geracioti TD Jr, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001; 158:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/32\">",
"      van der Kolk BA. The psychobiology of posttraumatic stress disorder. J Clin Psychiatry 1997; 58 Suppl 9:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/33\">",
"      Kilpatrick DG, Koenen KC, Ruggiero KJ, et al. The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. Am J Psychiatry 2007; 164:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/34\">",
"      Broekman BF, Olff M, Boer F. The genetic background to PTSD. Neurosci Biobehav Rev 2007; 31:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/35\">",
"      Binder EB, Bradley RG, Liu W, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008; 299:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/36\">",
"      Breslau N, Chilcoat HD, Kessler RC, Davis GC. Previous exposure to trauma and PTSD effects of subsequent trauma: results from the Detroit Area Survey of Trauma. Am J Psychiatry 1999; 156:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/37\">",
"      Schnyder U, Moergeli H, Klaghofer R, Buddeberg C. Incidence and prediction of posttraumatic stress disorder symptoms in severely injured accident victims. Am J Psychiatry 2001; 158:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/38\">",
"      Halbauer JD, Ashford JW, Zeitzer JM, et al. Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury. J Rehabil Res Dev 2009; 46:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/39\">",
"      Schneiderman AI, Braver ER, Kang HK. Understanding sequelae of injury mechanisms and mild traumatic brain injury incurred during the conflicts in Iraq and Afghanistan: persistent postconcussive symptoms and posttraumatic stress disorder. Am J Epidemiol 2008; 167:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/40\">",
"      Davidson JR, Hughes D, Blazer DG, George LK. Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med 1991; 21:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/41\">",
"      Smid GE, Mooren TT, van der Mast RC, et al. Delayed posttraumatic stress disorder: systematic review, meta-analysis, and meta-regression analysis of prospective studies. J Clin Psychiatry 2009; 70:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/42\">",
"      Solomon SD, Davidson JR. Trauma: prevalence, impairment, service use, and cost. J Clin Psychiatry 1997; 58 Suppl 9:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/43\">",
"      Wilcox HC, Storr CL, Breslau N. Posttraumatic stress disorder and suicide attempts in a community sample of urban american young adults. Arch Gen Psychiatry 2009; 66:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/44\">",
"      Bernal M, Haro JM, Bernert S, et al. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord 2007; 101:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/45\">",
"      Taft CT, Watkins LE, Stafford J, et al. Posttraumatic stress disorder and intimate relationship problems: a meta-analysis. J Consult Clin Psychol 2011; 79:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/46\">",
"      Schnurr PP, Hayes AF, Lunney CA, et al. Longitudinal analysis of the relationship between symptoms and quality of life in veterans treated for posttraumatic stress disorder. J Consult Clin Psychol 2006; 74:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/47\">",
"      Monson CM, Fredman SJ, Macdonald A, et al. Effect of cognitive-behavioral couple therapy for PTSD: a randomized controlled trial. JAMA 2012; 308:700.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/49\">",
"      Hoge CW, Castro CA, Messer SC, et al. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 2004; 351:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/50\">",
"      Wilson JF. Posttraumatic stress disorder needs to be recognized in primary care. Ann Intern Med 2007; 146:617.",
"     </a>",
"    </li>",
"    <li>",
"     Weathers FW, Juska JA, Keane TM. The PTSD checklist - civilian version. Boston National Center for PTSD. Boston Veterans Affairs Medical Center 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/52\">",
"      Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA. Psychometric properties of the PTSD Checklist (PCL). Behav Res Ther 1996; 34:669.",
"     </a>",
"    </li>",
"    <li>",
"     Weathers, FW, Huska, JA, Keane, TM. The PTSD Checklist Civilian Version (PCL-C) Boston, MA: National Center for PTSD (Boston Veterans Affairs Medical Center.1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/54\">",
"      Andrykowski MA, Cordova MJ, Studts JL, Miller TW. Posttraumatic stress disorder after treatment for breast cancer: prevalence of diagnosis and use of the PTSD Checklist-Civilian Version (PCL-C) as a screening instrument. J Consult Clin Psychol 1998; 66:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27352/abstract/55\">",
"      Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress 1995; 8:75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 500 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-BCBD45DDC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27352=[""].join("\n");
var outline_f26_45_27352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence and susceptibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Sexual assault",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mass conflict and displacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Combat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - ICU hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15162345\">",
"      - Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Co-occurring conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Instruments for screening and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Differentiating acute stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/500|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?16/39/17013\" title=\"form 1\">",
"      PTSD checklist civilian",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?13/7/13429\" title=\"form 2\">",
"      PTSD checklist military",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/500|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/55/9085\" title=\"table 1\">",
"      Diagnosis posttraumatic stress disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=related_link\">",
"      Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=related_link\">",
"      Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/45/8914?source=related_link\">",
"      Patient information: Post-traumatic stress disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=related_link\">",
"      Treatment of acute stress disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_45_27353="Midtrimester preterm premature rupture of membranes";
var content_f26_45_27353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Midtrimester preterm premature rupture of membranes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27353/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27353/contributors\">",
"     Thomas McElrath, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27353/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27353/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/45/27353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Midtrimester preterm premature rupture of the fetal membranes (PPROM) typically refers to spontaneous rupture of membranes at 16 to 26 weeks of gestation. This is an arbitrary definition, which varies slightly among investigators. Midtrimester PPROM complicates 0.4 to 0.7 percent of pregnancies, and is associated with significant fetal and neonatal",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology, diagnosis, and complications of midtrimester PPROM will be reviewed here. The management of PPROM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Midtrimester PPROM may be spontaneous or iatrogenic (eg, due to invasive procedures such as cervical surgery, amniocentesis, chorionic villus sampling).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spontaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of PPROM is not well understood. There are multiple etiologies, mechanical and physiological, that probably share a final common pathway leading to membrane rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43175?source=see_link&amp;anchor=H15#H15\">",
"     \"Fetal membranes: Anatomy and biochemistry\", section on 'Pathogenesis of rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for PPROM are similar to those for preterm labor (",
"    <a class=\"graphic graphic_table graphicRef68992 \" href=\"UTD.htm?27/48/28428\">",
"     table 1",
"    </a>",
"    ). The major risk factors appear to be a history of preterm labor, PPROM, or cervical insufficiency; multiple gestation; and antepartum bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     After invasive procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic amniocentesis is the most common procedure associated with midtrimester PPROM, which occurs with 1 to 2 percent of procedures. In contrast to spontaneous PPROM, leakage of amniotic fluid shortly after genetic amniocentesis is usually not associated with adverse outcome because the membranes usually \"reseal.\" Possible reasons cessation of leaking after amniocentesis is more likely than after spontaneous rupture are that the rupture site is very small, not proximate to the cervix, and composed of otherwise healthy membranes. (See",
"    <a class=\"local\" href=\"#H16728062\">",
"     'Resealing and reaccumulation of fluid'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnostic amniocentesis\", section on 'Leakage of amniotic fluid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other invasive midtrimester procedures, such as fetoscopy and percutaneous umbilical blood sampling, can also cause midtrimester PPROM. The risk is highest with fetoscopy. Clinical experience suggests that the risk is related to the number and diameter of ports and the duration of manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/4\">",
"     4",
"    </a>",
"    ]. Single port operative procedures are associated with a 6 to 10 percent incidence; the risk is lower for diagnostic procedures, but much higher for operative procedures using two or more ports and involving long operating times (such as used for cord ligation).",
"   </p>",
"   <p>",
"    Rupture of membranes at or after cerclage placement has a poorer outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link&amp;anchor=H15#H15\">",
"     \"Transvaginal cervical cerclage\", section on 'Management after PPROM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of midtrimester PPROM is based upon a characteristic history (leaking fluid from the vagina) and physical examination (visualization of fluid flowing from the endocervical canal), supplemented by laboratory tests in cases of diagnostic uncertainty. Ultrasound examination is performed to assess amniotic fluid volume and fetal size, and to perform a structural survey. The clinical manifestations and diagnosis of PROM are the same across gestation and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H4#H4\">",
"     \"Preterm premature rupture of membranes\", section on 'Clinical manifestations and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREGNANCY COMPLICATIONS AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling the patient with midtrimester PPROM is complicated by the small size and retrospective nature of the multiple studies on this subject. The majority of these reports refer to a single institutional experience, frequently prior to the widespread use of antepartum antibiotic prophylaxis, antepartum glucocorticoids to accelerate fetal lung maturation, and neonatal surfactant therapy. In addition, these studies often have differing",
"    <span class=\"nowrap\">",
"     inclusion/exclusion",
"    </span>",
"    and diagnostic criteria. In previable PPROM, patients who choose expectant management may be different from those who choose pregnancy termination, and these differences may influence other outcomes. Despite these limitations, this body of work provides remarkably consistent conclusions and estimation of the magnitude of risk with expectant management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Latency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time interval between membrane rupture and delivery is a critical factor in determining outcome in midtrimester PPROM, given that many of these pregnancies are previable or at the border of viability. To evaluate this relationship, we performed a review of English language studies of outcome after midtrimester PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5-18\">",
"     5-18",
"    </a>",
"    ]. Major findings from analysis of these studies were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The weighted mean gestational age at PPROM was 23.5 weeks of gestation.",
"     </li>",
"     <li>",
"      The weighted mean latency from gestational age at PPROM to delivery was 17 days.",
"     </li>",
"     <li>",
"      The weighted median latency was 6.8 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The large difference between mean and median latency is because the majority of pregnancies complicated by midtrimester PPROM deliver soon after presentation; fewer than 50 percent of patients remain pregnant beyond the first week after rupture. By 28 days post-rupture, 73 to 88 percent of pregnancies complicated by midtrimester PPROM have delivered. However, for pregnancies not delivering within the first 24 hours, the mean latency is 10 to 14 days.",
"   </p>",
"   <p>",
"    Several authors have suggested there is an inverse relation between latency and gestational age at rupture: earlier ruptures have longer latencies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/6,9,11,12,15,16,19\">",
"     6,9,11,12,15,16,19",
"    </a>",
"    ]. However, this inverse correlation may represent the effect of 'right censoring' by excluding patients who delivered shortly after arriving on the labor floor; these patients are more likely to be at an advanced gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chorioamnionitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorioamnionitis complicates 8 to 77 percent of midtrimester PPROM, with an average of 30 to 50 percent in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5-17\">",
"     5-17",
"    </a>",
"    ]. A portion of this variation is due to differences in criteria used to diagnose infection and differences in use of antibiotic prophylaxis. Chorioamnionitis is more common in pregnancies with midtrimester PPROM than in pregnancies without PPROM delivering at a similar gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/14,16,20\">",
"     14,16,20",
"    </a>",
"    ], or in pregnancies with PPROM occurring later in gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chorioamnionitis can be a cause or a result of PPROM. It may cause PPROM because infection of intact membranes weakens them, thereby facilitating rupture; it can be a sequelae of PPROM because ruptured membranes are less effective as a barrier to transcervical migration of cervicovaginal bacteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43175?source=see_link\">",
"     \"Fetal membranes: Anatomy and biochemistry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chorioamnionitis typically develops early in the latency period; more than one-half of cases occur within the first seven days after rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5-7,10\">",
"     5-7,10",
"    </a>",
"    ]. The maximum clinical occurrence is on the second through fifth day after rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/7,23\">",
"     7,23",
"    </a>",
"    ]. After the first week of latency, the incidence of chorioamnionitis falls dramatically [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/6,7,9,10,24,25\">",
"     6,7,9,10,24,25",
"    </a>",
"    ]. The higher frequency of clinical chorioamnionitis early in the latency period suggests that subclinical infection was likely present prior to membrane rupture, and may have been the cause.",
"   </p>",
"   <p>",
"    Chorioamnionitis is associated with onset of preterm labor and delivery, thus it is the major cause of short latency. The risk of developing chorioamnionitis after PPROM is increased in women with very low residual amniotic fluid volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/13\">",
"     13",
"    </a>",
"    ], and those who undergo digital cervical examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/26\">",
"     26",
"    </a>",
"    ]. The observation that the incidence of chorioamnionitis falls with prolonged latency implies that intrauterine infection may actually be less associated with delivery in the longer latency cases than it is in cases that deliver shortly after membrane rupture. This observation has been corroborated by a report that noted that the frequency of inflammatory pathology observed on neonatal head ultrasounds decreased in fetuses delivered after longer latency intervals compared with those delivering after shorter latency periods [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chorioamnionitis can also lead to maternal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/27\">",
"     27",
"    </a>",
"    ], but this is unusual with appropriate intervention (eg, antibiotic therapy and delivery). A review of the literature published after 1993 noted only one report of maternal sepsis among 131 women with PPROM &le;24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Placental abruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abruptio placentae is more common in pregnancies with midtrimester PPROM than in the general obstetric population, 2 to 44 percent versus 0.4 to 1.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/13\">",
"     13",
"    </a>",
"    ]. Among PPROM pregnancies, the risk of abruption correlates inversely with gestational age at rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/15,28\">",
"     15,28",
"    </a>",
"    ]. As an example, the incidence of abruption is 40 to 50 percent in PPROM prior to 20 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/15,28\">",
"     15,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic abruption is likely one cause of PPROM. There is abundant evidence that thrombin enhances fetal membrane",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decidual cytokine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protease production and theoretically could exacerbate membrane damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis of spontaneous preterm birth\", section on 'Decidual hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cord prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of cord prolapse during expectant management of patients with PPROM is small, but should be considered due to the potential for an adverse outcome. A review of nine studies including 731 patients with PPROM reported a 1.9 percent incidence of cord prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29494?source=see_link\">",
"     \"Umbilical cord prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fetal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of fetal death after midtrimester PPROM varies widely; we calculated a weighted average risk of 9.8 percent among 1439 pregnancies described in 18 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5-9,11-17,19,24,25,34,35\">",
"     5-9,11-17,19,24,25,34,35",
"    </a>",
"    ]. A systematic review of studies of fetal outcome following PPROM at less than 23 weeks reported a fetal death rate of 33 percent (95% CI 27 to 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, this is not a rare occurrence.",
"   </p>",
"   <p>",
"    The risk of intrauterine fetal death is inversely related to gestational age at PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/10,17\">",
"     10,17",
"    </a>",
"    ]. This relationship was illustrated in a study of fetal death in PPROM pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/10\">",
"     10",
"    </a>",
"    ]. The prevalence of fetal death prior to 20 weeks, prior to 24 weeks, and after 25 weeks was 33, 20, and 0 percent, respectively.",
"   </p>",
"   <p>",
"    Fetal demise in midtrimester PPROM is usually caused by abruption, cord prolapse, or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/10,17\">",
"     10,17",
"    </a>",
"    ]. There is probably less intervention for these complications at very early compared to later gestational ages.",
"   </p>",
"   <p>",
"    Residual amniotic fluid seems to be protective against intrauterine fetal death. All deaths in one series occurred in pregnancies in which the largest fluid pocket was &lt;2 cm in greatest diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal heart rate abnormalities necessitating cesarean delivery are more common due to the high prevalence of oligohydramnios and chorioamnionitis. The cesarean delivery rate is also increased because of a higher incidence of fetal malpresentation at early gestational ages. A classical uterine incision may be required since the lower uterine segment is often poorly developed in the second and early third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Retained placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of retained placenta (9 to 18 percent) necessitating either uterine exploration or curettage is increased with midtrimester PPROM, and especially if membrane rupture occurs prior to 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Postpartum endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum endometritis occurs in up to 40 percent of women with midtrimester PPROM; we calculated a weighted cumulative average risk of approximately 13 percent from our review of the literature. Postpartum maternal sepsis is less common (0 to 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5-17,25\">",
"     5-17,25",
"    </a>",
"    ]. The risk of maternal infection is inversely proportional to the latency period. As an example, one study reported postpartum intrauterine infection in 67 percent of patients with latencies of 24 to 72 hours; however, this risk declined to 10 percent after the fourth day [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16728062\">",
"    <span class=\"h1\">",
"     RESEALING AND REACCUMULATION OF FLUID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 14 percent of gravidas with spontaneous midtrimester PPROM eventually stop leaking amniotic fluid, presumably due to \"resealing\" of the fetal membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/7,14,38\">",
"     7,14,38",
"    </a>",
"    ]. Cessation of leakage is probably not due to actual repair and regeneration of the membranes, but rather to changes in the decidua and myometrium that block further leakage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/39\">",
"     39",
"    </a>",
"    ]. This subgroup of pregnancies has outcomes comparable to pregnancies uncomplicated by amniorrhexis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second subset of patients continue to leak fluid, but have partial reaccumulation of amniotic fluid. Approximately 25 percent of patients with midtrimester PPROM reaccumulate fluid on ultrasound examination with expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with iatrogenic midtrimester PPROM after amniocentesis usually \"reseal\" membranes within a week and have good pregnancy outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnostic amniocentesis\", section on 'Leakage of amniotic fluid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PEDIATRIC OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neonatal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of studies of fetal outcome following PPROM at less than 23 weeks reported perinatal death (fetal and early neonatal deaths) in 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/36\">",
"     36",
"    </a>",
"    ]. The mortality rate after midtrimester PPROM is high, primarily due to the short latency period, which results in an early gestational age at delivery (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Latency'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5-17,19,24,25,34,35,40-43\">",
"     5-17,19,24,25,34,35,40-43",
"    </a>",
"    ]. The neonatal mortality rate in midtrimester PPROM is similar to that for controls without PPROM matched for gestational age (",
"    <a class=\"graphic graphic_figure graphicRef54530 \" href=\"UTD.htm?24/45/25310\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/16,25\">",
"     16,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since mean latency in midtrimester PPROM is 17 days, PPROM occurring at 23 to 24 weeks of gestation is more likely to be associated with neonatal survival than PPROM before 22 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/8,10,13,17,38,44\">",
"     8,10,13,17,38,44",
"    </a>",
"    ]. Neonatal survival improves significantly after 24 to 25 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/9,11,25\">",
"     9,11,25",
"    </a>",
"    ]. In a review of three studies of PPROM at 14 or 16 to 24 weeks, survival after conservatively managed PPROM at &lt;22&nbsp;weeks was significantly lower than PPROM occurring at 22 to 24&nbsp;weeks",
"    <span class=\"nowrap\">",
"     (8/57",
"    </span>",
"    [14.4 percent] versus",
"    <span class=\"nowrap\">",
"     30/52",
"    </span>",
"    [57.7] percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/3\">",
"     3",
"    </a>",
"    ]. These data likely overstate survival because of exclusion of patients electing pregnancy terminations for persistent fluid leakage, oligohydramnios, abnormal ultrasound findings, or other issues.",
"   </p>",
"   <p>",
"    The risk of neonatal mortality is also correlated with residual amniotic fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/13,17,35,42\">",
"     13,17,35,42",
"    </a>",
"    ]. Pregnancies with a fluid pocket &ge;2 cm have a higher neonatal survival rate than those with a largest fluid pocket of &lt;2 cm (98 versus 31 percent) for neonates delivering at the same gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survival rate for pregnancies associated with iatrogenic PPROM is several-fold higher than that for spontaneous PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/45\">",
"     45",
"    </a>",
"    ]. This may be related to a lower rate of infection, higher residual amniotic fluid volume, higher rate of resealing, or other factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Morbidity related to preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for long-term intact survival, even among those infants achieving hospital discharge, is only fair. In one large retrospective review of infants delivered from pregnancies complicated by midtrimester PPROM, only 50 percent had a normal neurologic examination at 2 years of corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/46\">",
"     46",
"    </a>",
"    ]. Short- and long-term morbidity is common and related to gestational age at birth. The frequencies of these complications (eg, retinopathy of prematurity, intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, patent ductus arteriosus, nosocomial infection, deafness, and necrotizing enterocolitis) by gestational age are reviewed in detail separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"       \"Short-term complications of the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13814?source=see_link\">",
"       \"Long-term complications of the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"       \"Incidence and mortality of the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Morbidity related to infection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Meningitis",
"     </li>",
"     <li>",
"      Pneumonia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"       \"Neonatal pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to short-term infectious complications, in utero infection can result in long-term neurodevelopmental disability:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link&amp;anchor=H19#H19\">",
"       \"Intraamniotic infection (chorioamnionitis)\", section on 'Neurodevelopmental outcome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link&amp;anchor=H14#H14\">",
"       \"Short-term complications of the premature infant\", section on 'Infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Outcome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link\">",
"       \"Periventricular leukomalacia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pulmonary hypoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of pulmonary hypoplasia in neonates of pregnancies complicated by midtrimester PPROM varies widely, but averages 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5-17,19,24,25,34,35\">",
"     5-17,19,24,25,34,35",
"    </a>",
"    ]. The mortality rate for these neonates is 70 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/15,17,24,34,37\">",
"     15,17,24,34,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gestational age at the time of membrane rupture is the critical factor in the risk of subsequent neonatal pulmonary hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5,17-19,24,47\">",
"     5,17-19,24,47",
"    </a>",
"    ]. One study noted a 46 percent decrease in the odds of pulmonary hypoplasia with each additional week of gestation after midtrimester PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/34\">",
"     34",
"    </a>",
"    ]. Several series have reported a low incidence (less than 1.4 percent) of pulmonary hypoplasia when PPROM occurred after 26 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/15,18,19,24,34\">",
"     15,18,19,24,34",
"    </a>",
"    ]. This gestational age corresponds to the end of the canalicular stage of lung development, after which the developing acinar structure becomes less sensitive to external perturbations (",
"    <a class=\"graphic graphic_table graphicRef72141 \" href=\"UTD.htm?15/43/16059\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of oligohydramnios is an additional risk factor for pulmonary hypoplasia; lower volumes of residual fluid confer the highest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/17,35,37\">",
"     17,35,37",
"    </a>",
"    ]. This was illustrated in a study that found the incidence of pulmonary hypoplasia with severe, moderate, and no to mild oligohydramnios was 43, 19, and 7 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is less clear whether there is an association between the length of the latency period and risk of pulmonary hypoplasia. One study found the median latency period was longer in cases of pulmonary hypoplasia than in those without (31 and 7 days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/16\">",
"     16",
"    </a>",
"    ]. However, this finding may represent a relationship between earlier gestational age at rupture and longer latency rather than an independent effect of the latency period itself. Other authors have not confirmed this association [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/34,37\">",
"     34,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lethal pulmonary hypoplasia is difficult to diagnosis antepartum. A variety of sonographic methods have been evaluated (eg, thoracic circumference, thoracic:abdominal ratio), but no method has proven sufficiently reliable for clinical decision-making [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Musculoskeletal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most limb development is in the embryonic period [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/50\">",
"     50",
"    </a>",
"    ]. The appendicular skeleton is premolded in cartilage by the end of this period and ossification centers first appear between 12 and 14 weeks postmenstrual age. The majority of limb growth occurs in the second and third trimesters. Asymmetric intrauterine pressure and restriction in fetal movement associated with midtrimester PPROM can lead to deformities of variable severity in previously normally formed extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/51\">",
"     51",
"    </a>",
"    ]. An increased likelihood of skeletal deformities has been observed among infants diagnosed with pulmonary hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/19,24,34\">",
"     19,24,34",
"    </a>",
"    ], suggesting that the two disorders have a common etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link&amp;anchor=H31#H31\">",
"     \"Genetic and environmental causes of birth defects\", section on 'Deformations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of skeletal deformities varies widely among studies; the mean incidence is 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/5-17,19,24,25,34,35\">",
"     5-17,19,24,25,34,35",
"    </a>",
"    ]. In contrast to pulmonary hypoplasia, the gestational age at PPROM is not a significant determinant of the risk of skeletal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/19,24,34,35\">",
"     19,24,34,35",
"    </a>",
"    ]. This difference is likely due to the progressive and continuous development of the axial skeleton, which is unmarked by the phases of biochemical maturation that are observed in the lung. Thus, a severe insult of prolonged duration, regardless of gestational age, should be more predictive of the development of skeletal than pulmonary abnormalities.",
"   </p>",
"   <p>",
"    This hypothesis is supported by several series that observed that the duration of latency and the severity of oligohydramnios independently increase the risk of skeletal abnormalities and act synergistically to raise the risk beyond the effect of either variable alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/19,24,34\">",
"     19,24,34",
"    </a>",
"    ]. As an example, one study reported the risk of skeletal abnormality was two-fold higher in pregnancies with midtrimester PPROM complicated by severe oligohydramnios (defined as largest pocket less than 1 cm) than in matched pregnancies with normal or mildly reduced fluid (26 versus 54 percent); the risk was highest after 14 days of latency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limb deformations related to midtrimester PPROM do not generally require surgical correction as they gradually resolve with postnatal growth and development [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of midtrimester PPROM is similar to that for PPROM later in gestation, with a few differences at previable gestations. As an example, prior to viability expectant management in the patient's home is reasonable in stable pregnancies; antenatal glucocorticoids, tocolytics, and prophylactic antibiotics are not usually administered; and pregnancy termination may be an option. Management of PPROM is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little evidence to support antenatal glucocorticoid use prior to 23 weeks of gestation as there are only a few primitive alveoli at this gestational age on which antenatal glucocorticoids may exert an effect. Glucocorticoids should be administered at or after 23 weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data from many randomized trials suggested that antibiotic prophylaxis after membrane rupture increases latency by approximately a week, no similar trials have been performed among patients with midtrimester PPROM to support either the efficacy or safety of this therapy. Nevertheless, use of broad spectrum antibiotics is a common practice [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/3\">",
"     3",
"    </a>",
"    ] based on data from observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/25,42,52\">",
"     25,42,52",
"    </a>",
"    ] and extrapolation of results from randomized trials at later gestational ages. It has been our practice, however, not to utilize antibiotic prophylaxis in the patient with midtrimester PPROM prior to 23 weeks of gestation, as at these earlier gestational ages, the potential addition of one week of gestation, on average, rarely has benefit in the overall context of fetal development and possible neonatal morbidity. Additionally, even in studies reporting aggressive antibiotic and surgical management after midtrimester membrane rupture, the combined incidence of fetal and neonatal death remains high (37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Group B streptococcus cultures are obtained and prophylaxis initiated per standard guidelines. While it has been our practice to obtain cultures upon presentation, as was noted above, we will only initiate Group B streptococcus prophylaxis if there is a high risk of delivery after 23 to 24 weeks of gestation, when an expectation of neonatal survival exists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link&amp;anchor=H15#H15\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Preterm premature rupture of membranes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of tocolysis is controversial; there are inadequate data on which to make an evidence-based recommendation for or against short-term use. The major potential benefit is to prolong latency long enough to allow administration of a full course of antenatal corticosteroids to pregnancies over 23 weeks of gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H22#H22\">",
"     \"Preterm premature rupture of membranes\", section on 'Tocolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of amnioinfusion is also controversial, with only sparse data available in PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/54\">",
"     54",
"    </a>",
"    ]. More studies of the safety and efficacy of the procedure in this setting are needed before prophylactic amnioinfusion can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=see_link&amp;anchor=H10#H10\">",
"     \"Amnioinfusion: Indications\", section on 'Preterm premature rupture of membranes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, early gestational age at membrane rupture is associated with a variety of adverse neonatal outcomes (infection, neurodevelopment delay); however, gains in fetal maturity from expectant management appear to outweigh these risks at very early gestations (",
"    <a class=\"graphic graphic_figure graphicRef54530 \" href=\"UTD.htm?24/45/25310\">",
"     figure 1",
"    </a>",
"    ). Furthermore, prolonged latency in these patients is not associated with an increasing frequency of abnormal neonatal cranial ultrasound examination and there is no evidence that elective early delivery will prevent many of these adverse sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/23,55\">",
"     23,55",
"    </a>",
"    ]. However, evidence of clinical infection, abruptio placenta, or fetal compromise are indications for delivery as expectant management in these situations can increase maternal or neonatal morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Repair of leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tissue sealants (eg, fibrin glue, gelatin sponge, amniopatch) have shown some success in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/39\">",
"     39",
"    </a>",
"    ]. Neither the safety nor the efficacy of these sealants has been established. Furthermore, thrombin may trigger fetal membrane matrix",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decidual metalloproteinase and inflammatory cytokine production and myometrial contractions, theoretically promoting further membrane damage and premature delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/29,31,33,56\">",
"     29,31,33,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraamniotic injection of platelets and cryoprecipitate (ie, amniopatch) has also been used to treat iatrogenic rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Although sometimes successful, the procedure has been associated with unexpected fetal death and should be considered investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Retained placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been our clinical practice, in the absence of clinically significant hemorrhage, to allow up to 60 minutes for the delivery of the placenta before moving on to surgical evacuation. We have given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    1000 mg rectally if the placenta does not immediately deliver; however, there is some evidence that administration of PGF2-alpha may be preferable for avoiding postpartum dilatation and evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Coexistent cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether the presence of foreign material in the cervix after cerclage placement increases the risk of maternal or neonatal sepsis in the setting of PPROM; the most appropriate management in this clinical setting remains controversial. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link&amp;anchor=H15#H15\">",
"     \"Transvaginal cervical cerclage\", section on 'Management after PPROM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with PPROM are at high risk of recurrence in subsequent pregnancies, if remediable factors such as invasive procedures and cigarette smoking are not corrected. Recurrent PPROM occurs in 14 to 32 percent of patients with PPROM and two consecutive pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. There is no clear association between the gestational age at the time of rupture in the index pregnancy, latency period, interval between pregnancies, and the probability of recurrent PPROM in the next pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27353/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a history of cervical incompetence in a prior pregnancy are probably at increased risk of midtrimester PPROM in a subsequent pregnancy, given the common etiology of both entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39249?source=see_link\">",
"       \"Patient information: Preterm premature rupture of membranes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Midtrimester preterm premature rupture of membranes (PPROM) complicates approximately 0.7 percent of pregnancies. It is often a complication of invasive obstetrical procedures; PPROM after amniocentesis has a much better prognosis than spontaneous midtrimester PPROM. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The time interval between membrane rupture and delivery is a critical factor in determining outcome, given that many of these pregnancies are previable or at the border of viability. The mean latency from gestational age at PPROM to delivery is about 17 days and the median latency is about one week, since the majority of pregnancies deliver soon after rupture of membranes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Latency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal survival is primarily related to gestational age at delivery, and is comparable to that in preterm deliveries matched for gestational age without PPROM. For these very early gestations, gains in fetal maturity with expectant management dramatically improve survival. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neonatal death'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy complications associated with midtrimester PPROM include increased risks of infection (chorioamnionitis, endometritis), abruptio placentae, cord prolapse, fetal death, preterm birth, and need for cesarean delivery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pregnancy complications and outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neonate is at risk for",
"      <span class=\"nowrap\">",
"       morbidity/mortality",
"      </span>",
"      related to preterm birth, infection, pulmonary hypoplasia, and musculoskeletal deformation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pediatric outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cessation of amniotic fluid leakage with reaccumulation of amniotic fluid confers a prognosis comparable to that of pregnancies without PPROM. (See",
"      <a class=\"local\" href=\"#H16728062\">",
"       'Resealing and reaccumulation of fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antenatal glucocorticoids after 23 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The efficacy of antenatal glucocorticoids prior to 23 weeks of gestation has not been demonstrated. The fetus has only a few primitive alveoli this early in gestation, which may limit the effectiveness of glucocorticoid treatment. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The safety and efficacy of tissue sealants for repair of PPROM have not been established. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Repair of leaks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/1\">",
"      Schucker JL, Mercer BM. Midtrimester premature rupture of the membranes. Semin Perinatol 1996; 20:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/2\">",
"      ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2007; 109:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/3\">",
"      Waters TP, Mercer BM. The management of preterm premature rupture of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009; 201:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/4\">",
"      Gratac&oacute;s E, Deprest J. Current experience with fetoscopy and the Eurofoetus registry for fetoscopic procedures. Eur J Obstet Gynecol Reprod Biol 2000; 92:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/5\">",
"      Moretti M, Sibai BM. Maternal and perinatal outcome of expectant management of premature rupture of membranes in the midtrimester. Am J Obstet Gynecol 1988; 159:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/6\">",
"      Taylor J, Garite TJ. Premature rupture of membranes before fetal viability. Obstet Gynecol 1984; 64:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/7\">",
"      Beydoun SN, Yasin SY. Premature rupture of the membranes before 28 weeks: conservative management. Am J Obstet Gynecol 1986; 155:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/8\">",
"      Dowd J, Permezel M. Pregnancy outcome following preterm premature rupture of the membranes at less than 26 weeks' gestation. Aust N Z J Obstet Gynaecol 1992; 32:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/9\">",
"      Bengtson JM, VanMarter LJ, Barss VA, et al. Pregnancy outcome after premature rupture of the membranes at or before 26 weeks' gestation. Obstet Gynecol 1989; 73:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/10\">",
"      Major CA, Kitzmiller JL. Perinatal survival with expectant management of midtrimester rupture of membranes. Am J Obstet Gynecol 1990; 163:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/11\">",
"      Rib DM, Sherer DM, Woods JR Jr. Maternal and neonatal outcome associated with prolonged premature rupture of membranes below 26 weeks' gestation. Am J Perinatol 1993; 10:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/12\">",
"      Hibbard JU, Hibbard MC, Ismail M, Arendt E. Pregnancy outcome after expectant management of premature rupture of the membranes in the second trimester. J Reprod Med 1993; 38:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/13\">",
"      Hadi HA, Hodson CA, Strickland D. Premature rupture of the membranes between 20 and 25 weeks' gestation: role of amniotic fluid volume in perinatal outcome. Am J Obstet Gynecol 1994; 170:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/14\">",
"      Fortunato SJ, Welt SI, Eggleston MK Jr, Bryant EC. Active expectant management in very early gestations complicated by premature rupture of the fetal membranes. J Reprod Med 1994; 39:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/15\">",
"      Farooqi A, Holmgren PA, Engberg S, Serenius F. Survival and 2-year outcome with expectant management of second-trimester rupture of membranes. Obstet Gynecol 1998; 92:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/16\">",
"      Kurkinen-R&auml;ty M, Koivisto M, Jouppila P. Perinatal and neonatal outcome and late pulmonary sequelae in infants born after preterm premature rupture of membranes. Obstet Gynecol 1998; 92:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/17\">",
"      Shumway JB, Al-Malt A, Amon E, et al. Impact of oligohydramnios on maternal and perinatal outcomes of spontaneous premature rupture of the membranes at 18-28 weeks. J Matern Fetal Med 1999; 8:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/18\">",
"      Falk SJ, Campbell LJ, Lee-Parritz A, et al. Expectant management in spontaneous preterm premature rupture of membranes between 14 and 24 weeks' gestation. J Perinatol 2004; 24:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/19\">",
"      Nimrod C, Varela-Gittings F, Machin G, et al. The effect of very prolonged membrane rupture on fetal development. Am J Obstet Gynecol 1984; 148:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/20\">",
"      Arias F, Victoria A, Cho K, Kraus F. Placental histology and clinical characteristics of patients with preterm premature rupture of membranes. Obstet Gynecol 1997; 89:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/21\">",
"      Hillier SL, Martius J, Krohn M, et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/22\">",
"      Morales WJ. The effect of chorioamnionitis on the developmental outcome of preterm infants at one year. Obstet Gynecol 1987; 70:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/23\">",
"      McElrath TF, Allred EN, Leviton A, Development Epidemiology Network Investigators. Prolonged latency after preterm premature rupture of membranes: an evaluation of histologic condition and intracranial ultrasonic abnormality in the neonate born at &lt;28 weeks of gestation. Am J Obstet Gynecol 2003; 189:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/24\">",
"      Blott M, Greenough A. Neonatal outcome after prolonged rupture of the membranes starting in the second trimester. Arch Dis Child 1988; 63:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/25\">",
"      Morales WJ, Talley T. Premature rupture of membranes at &lt; 25 weeks: a management dilemma. Am J Obstet Gynecol 1993; 168:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/26\">",
"      Alexander JM, Mercer BM, Miodovnik M, et al. The impact of digital cervical examination on expectantly managed preterm rupture of membranes. Am J Obstet Gynecol 2000; 183:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/27\">",
"      Mabie WC, Barton JR, Sibai B. Septic shock in pregnancy. Obstet Gynecol 1997; 90:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/28\">",
"      Holmgren PA, Olofsson JI. Preterm premature rupture of membranes and the associated risk for placental abruption. Inverse correlation to gestational length. Acta Obstet Gynecol Scand 1997; 76:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/29\">",
"      Lockwood CJ, Toti P, Arcuri F, et al. Mechanisms of abruption-induced premature rupture of the fetal membranes: thrombin-enhanced interleukin-8 expression in term decidua. Am J Pathol 2005; 167:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/30\">",
"      Cakmak H, Schatz F, Huang ST, et al. Progestin suppresses thrombin- and interleukin-1beta-induced interleukin-11 production in term decidual cells: implications for preterm delivery. J Clin Endocrinol Metab 2005; 90:5279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/31\">",
"      Mackenzie AP, Schatz F, Krikun G, et al. Mechanisms of abruption-induced premature rupture of the fetal membranes: Thrombin enhanced decidual matrix metalloproteinase-3 (stromelysin-1) expression. Am J Obstet Gynecol 2004; 191:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/32\">",
"      Rosen T, Schatz F, Kuczynski E, et al. Thrombin-enhanced matrix metalloproteinase-1 expression: a mechanism linking placental abruption with premature rupture of the membranes. J Matern Fetal Neonatal Med 2002; 11:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/33\">",
"      Stephenson CD, Lockwood CJ, Ma Y, Guller S. Thrombin-dependent regulation of matrix metalloproteinase (MMP)-9 levels in human fetal membranes. J Matern Fetal Neonatal Med 2005; 18:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/34\">",
"      Rotschild A, Ling EW, Puterman ML, Farquharson D. Neonatal outcome after prolonged preterm rupture of the membranes. Am J Obstet Gynecol 1990; 162:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/35\">",
"      Kilbride HW, Yeast J, Thibeault DW. Defining limits of survival: lethal pulmonary hypoplasia after midtrimester premature rupture of membranes. Am J Obstet Gynecol 1996; 175:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/36\">",
"      Dewan H, Morris JM. A systematic review of pregnancy outcome following preterm premature rupture of membranes at a previable gestational age. Aust N Z J Obstet Gynaecol 2001; 41:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/37\">",
"      Vergani P, Ghidini A, Locatelli A, et al. Risk factors for pulmonary hypoplasia in second-trimester premature rupture of membranes. Am J Obstet Gynecol 1994; 170:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/38\">",
"      Shenker L, Reed KL, Anderson CF, Borjon NA. Significance of oligohydramnios complicating pregnancy. Am J Obstet Gynecol 1991; 164:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/39\">",
"      Devlieger R, Millar LK, Bryant-Greenwood G, et al. Fetal membrane healing after spontaneous and iatrogenic membrane rupture: a review of current evidence. Am J Obstet Gynecol 2006; 195:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/40\">",
"      Hoekstra JH, de Boer R. Very early prolonged premature rupture of membranes and survival. Eur J Pediatr 1990; 149:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/41\">",
"      Dinsmoor MJ, Bachman R, Haney EI, et al. Outcomes after expectant management of extremely preterm premature rupture of the membranes. Am J Obstet Gynecol 2004; 190:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/42\">",
"      Grisaru-Granovsky S, Eitan R, Kaplan M, Samueloff A. Expectant management of midtrimester premature rupture of membranes: a plea for limits. J Perinatol 2003; 23:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/43\">",
"      Manuck TA, Eller AG, Esplin MS, et al. Outcomes of expectantly managed preterm premature rupture of membranes occurring before 24 weeks of gestation. Obstet Gynecol 2009; 114:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/44\">",
"      McElrath TF, Robinson JN, Ecker JL, et al. Neonatal outcome of infants born at 23 weeks' gestation. Obstet Gynecol 2001; 97:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/45\">",
"      Chauleur C, Rochigneux S, Seffert P, et al. Neonatal outcomes and four-year follow-up after spontaneous or iatrogenic preterm prelabor rupture of membranes before 24 weeks. Acta Obstet Gynecol Scand 2009; 88:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/46\">",
"      Pristauz G, Bauer M, Maurer-Fellbaum U, et al. Neonatal outcome and two-year follow-up after expectant management of second trimester rupture of membranes. Int J Gynaecol Obstet 2008; 101:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/47\">",
"      Lauria MR, Gonik B, Romero R. Pulmonary hypoplasia: pathogenesis, diagnosis, and antenatal prediction. Obstet Gynecol 1995; 86:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/48\">",
"      Glasser SW, Korfhagen TR, Wert SE, Whitsett JA. Transgenic models for study of pulmonary development and disease. Am J Physiol 1994; 267:L489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/49\">",
"      van Teeffelen AS, Van Der Heijden J, Oei SG, et al. Accuracy of imaging parameters in the prediction of lethal pulmonary hypoplasia secondary to mid-trimester prelabor rupture of fetal membranes: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2012; 39:495.",
"     </a>",
"    </li>",
"    <li>",
"     Orthopedic Problems, Chapter 48 in: Fanaroff AA and Martin RJ (eds.) Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant. Fifth edition. 1996 Mosby Year Book, St Louis.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/51\">",
"      Seeds AE, Hellegers AE. Acid-base determinations in human amniotic fluid throughout pregnancy. Am J Obstet Gynecol 1968; 101:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/52\">",
"      Xiao ZH, Andr&eacute; P, Lacaze-Masmonteil T, et al. Outcome of premature infants delivered after prolonged premature rupture of membranes before 25 weeks of gestation. Eur J Obstet Gynecol Reprod Biol 2000; 90:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/53\">",
"      Miyazaki K, Furuhashi M, Yoshida K, Ishikawa K. Aggressive intervention of previable preterm premature rupture of membranes. Acta Obstet Gynecol Scand 2012; 91:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/54\">",
"      Hofmeyr GJ, Essilfie-Appiah G, Lawrie TA. Amnioinfusion for preterm premature rupture of membranes. Cochrane Database Syst Rev 2011; :CD000942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/55\">",
"      Locatelli A, Ghidini A, Paterlini G, et al. Gestational age at preterm premature rupture of membranes: a risk factor for neonatal white matter damage. Am J Obstet Gynecol 2005; 193:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/56\">",
"      O'Sullivan CJ, Allen NM, O'Loughlin AJ, et al. Thrombin and PAR1-activating peptide: effects on human uterine contractility in vitro. Am J Obstet Gynecol 2004; 190:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/57\">",
"      Quintero RA, Morales WJ, Allen M, et al. Treatment of iatrogenic previable premature rupture of membranes with intra-amniotic injection of platelets and cryoprecipitate (amniopatch): preliminary experience. Am J Obstet Gynecol 1999; 181:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/58\">",
"      Contino B, Armellino F, Brokaj L, Patroncini S. Amniopatch, a repairing technique for premature rupture of amniotic membranes in second trimester. Acta Biomed 2004; 75 Suppl 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/59\">",
"      Cobo T, Borrell A, Fortuny A, et al. Treatment with amniopatch of premature rupture of membranes after first-trimester chorionic villus sampling. Prenat Diagn 2007; 27:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/60\">",
"      Richter J, Henry A, Ryan G, et al. Amniopatch procedure after previable iatrogenic rupture of the membranes: a two-center review. Prenat Diagn 2013; 33:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/61\">",
"      Sundaram S, Diaz JP, Gonz&aacute;lez-Quintero VH, Verma U. Rectal misoprostol vs 15-methyl prostaglandin F2alpha for retained placenta after second-trimester delivery. Am J Obstet Gynecol 2009; 200:e24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/62\">",
"      Asrat T, Lewis DF, Garite TJ, et al. Rate of recurrence of preterm premature rupture of membranes in consecutive pregnancies. Am J Obstet Gynecol 1991; 165:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/63\">",
"      Naeye RL. Factors that predispose to premature rupture of the fetal membranes. Obstet Gynecol 1982; 60:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/64\">",
"      Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999; 181:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27353/abstract/65\">",
"      Lee T, Carpenter MW, Heber WW, Silver HM. Preterm premature rupture of membranes: risks of recurrent complications in the next pregnancy among a population-based sample of gravid women. Am J Obstet Gynecol 2003; 188:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6741 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-86B232FEE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27353=[""].join("\n");
var outline_f26_45_27353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spontaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      After invasive procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREGNANCY COMPLICATIONS AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Latency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Placental abruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cord prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fetal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Retained placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16728062\">",
"      RESEALING AND REACCUMULATION OF FLUID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PEDIATRIC OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neonatal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Morbidity related to preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Morbidity related to infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pulmonary hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Musculoskeletal development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Repair of leaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Retained placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Coexistent cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6741|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/45/25310\" title=\"figure 1\">",
"      NNM by gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6741|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/48/28428\" title=\"table 1\">",
"      Risk factors for preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/43/16059\" title=\"table 2\">",
"      Phases lung development",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=related_link\">",
"      Amnioinfusion: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43175?source=related_link\">",
"      Fetal membranes: Anatomy and biochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13814?source=related_link\">",
"      Long-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39249?source=related_link\">",
"      Patient information: Preterm premature rupture of membranes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=related_link\">",
"      Periventricular leukomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=related_link\">",
"      Transvaginal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29494?source=related_link\">",
"      Umbilical cord prolapse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_45_27354="Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities";
var content_f26_45_27354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27354/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27354/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27354/contributors\">",
"     David C Harmon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27354/contributors\">",
"     Mark C Gebhardt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27354/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27354/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27354/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/45/27354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/45/27354/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/45/27354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas are rare malignant tumors that arise from extraskeletal connective tissues, including the peripheral nervous system. They can arise at any body site.",
"   </p>",
"   <p>",
"    Treatment for locally recurrent and locally advanced, initially unresectable soft tissue sarcoma (STS) of the extremities will be reviewed here. Issues relating to classification, diagnosis, and staging of STS, local treatment options for localized primary STS of the extremities and chest wall, the use of adjuvant and neoadjuvant chemotherapy for extremity STS, and the treatment of STS in locations other than the extremities and chest wall are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link\">",
"     \"Head and neck sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33146?source=see_link\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7794442\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF MULTIDISCIPLINARY EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their rarity and the frequent need for multimodality treatment, evaluation and management of soft tissue sarcomas should ideally be carried out in a center with expertise in the treatment of sarcomas, including surgical, orthopedic, medical, pediatric, and radiation oncology. The multidisciplinary team approach to care of soft tissue sarcomas optimizes treatment planning, minimizes duplication of diagnostic studies, reduces the time to implementation of the definitive therapeutic protocol, and the expertise gained by dedicated subspecialists improves clinical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LOCALLY RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 15 percent of patients with extremity STS who are treated with complete resection and adjunctive radiation therapy (RT) will develop a local tumor failure, the majority within the first two years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. A local recurrence is associated with a significant worsening of prognosis, although whether the local relapse is causative or simply a marker of worse tumor biology is debated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. At least in theory, the two mechanisms might coexist and possibly interact, with both contributing to outcomes.",
"   </p>",
"   <p>",
"    The approach to the patient with an isolated local recurrence is similar to that for primary disease with some modification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Reresection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is an important component of successful salvage therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/4\">",
"     4",
"    </a>",
"    ]. As with primary treatment, the goal is to salvage the limb with a limb sparing resection if possible. However, approximately 10 to 25 percent of patients with locally recurrent disease will not be amenable to local resection because of involvement of major nerves and blood vessels, bone or extensive soft tissue invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Possible alternatives to amputation in this setting include limb sparing surgery with adjuvant RT, chemoradiotherapy, or where available and appropriate, systemic chemotherapy with regional hyperthermia, and regional chemotherapy, which in Europe includes the use of tumor necrosis factor (TNF), an agent that is not available in the US. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Chemotherapy with regional hyperthermia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Regional chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adjunctive RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limb sparing surgery alone provides long-term local control in only a minority of patients unless wide margins completely around the tumor can be achieved. The amount of uninvolved tissue (thickness) remains controversial, but fascia margins of 2 to 3 mm are probably adequate, whereas 1 cm or more is desirable when the margin is skeletal muscle or fat. For patients whose primary treatment was surgery alone, reexcision is usually combined with RT, either given preoperatively or postoperatively.",
"   </p>",
"   <p>",
"    Many clinicians, including our group, favor preoperative RT for patients who have not had prior RT. A Canadian randomized trial of preoperative versus postoperative RT for primary (90 percent of the 190 enrolled patients) or locally recurrent (10 percent) extremity STS concluded that efficacy was similar using either approach, and that the higher rate of generally reversible acute wound healing complications in preoperatively treated patients was offset by a lower rate of generally irreversible late complications, including grade 3 to 4 fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H10#H10\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Preoperative versus postoperative RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have had prior RT and are going to receive additional RT, most clinicians favor adjuvant postoperative brachytherapy or intensity modulated RT (IMRT) to reduce the risk of wound healing problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preoperative chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal aim of preoperative treatment of STS is to improve local control and to facilitate resection by making the tumor smaller in some cases, less tethered to surrounding tissues, and less viable at its invasive borders. There is a clear rationale for concurrent chemoradiotherapy for patients with recurrent or large intermediate or high grade sarcomas larger than 8 cm given the radiosensitizing potential of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or any number of other chemotherapy drugs known to sensitize tissue to radiation. In general, full systemic doses of chemotherapy are not given, and as a result, the focus of such therapy is on enhancing local, rather than systemic disease control.",
"   </p>",
"   <p>",
"    However, the widespread acceptance of this approach for locally recurrent, previously unirradiated STS in clinical practice is limited by concerns as to higher rates of treatment-related toxicity and the lack of prospective trials comparing any form of chemoradiotherapy versus RT alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eilber and colleagues at UCLA initially popularized preoperative simultaneous regional chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    30 mg flat dose daily for three days) followed by RT (28 Gy in eight fractions) and limb preserving surgery in patients with high-grade extremity STS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. They were able to achieve a high rate of primary limb salvage, a low local recurrence rate (approximately 9 percent) and a 65 percent long-term survival rate.",
"   </p>",
"   <p>",
"    A number of other groups have utilized this regimen, also obtaining low rates of local recurrence with varying degrees of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. As an example, in a Southeastern Cancer Study Group trial, 66 patients with nonmetastatic high-grade extremity STS received intraarterial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (30 mg total dose over 24 hours daily for three days) infused directly into the vessel feeding the tumor, plus concurrent RT (30 Gy in 10 fractions, 35 Gy in 10 fractions, or 46 Gy in 23 to 25 fractions) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/18\">",
"     18",
"    </a>",
"    ]. Limb-sparing surgery was possible in 60 patients, and five-year overall and disease-free survival rates were 59 and 44 percent, respectively. Although the local failure rate was very low (1.5 percent), toxicity was significant. Wound complications developed in 41 percent of patients, two of whom required delayed amputation.",
"   </p>",
"   <p>",
"    It is not clear that intraarterial administration is necessary to achieve synergy between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and RT, and it is probably more toxic than the intravenous (IV) route. A randomized phase III study compared bolus doxorubicin administration by the intraarterial and IV routes, both in conjunction with preoperative RT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Although the data were never published in a final manuscript, a preliminary report noted no significant differences in the rates of limb salvage, local recurrence, complications, or histologically evident necrosis between the two treatment groups.",
"   </p>",
"   <p>",
"    Thus, there are no data to support a specific advantage for intraarterial as compared to IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    administration. Because it is less complicated to deliver and has less potential morbidity (at least for upper extremity tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/22\">",
"     22",
"    </a>",
"    ]), most groups who use this regimen administer IV rather than intraarterial chemotherapy during concurrent chemoradiation.",
"   </p>",
"   <p>",
"    More recent efforts have focused on reducing toxicity by combining concurrent low-dose IV infusional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    with preoperative RT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety and efficacy of this approach was shown in a phase I trial of 27 patients with potentially resectable intermediate or high-grade extremity or truncal STS [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/25\">",
"       25",
"      </a>",
"      ]. The maximally tolerated dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      was 17.5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week, given as an initial bolus (4",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      followed by a 96 hour continuous infusion. Treatment was extremely well tolerated. Among the 22 patients who received this dose concurrent with RT and who underwent surgery, 11 had &ge;90 percent tumor necrosis; in two cases, there was no tumor in the resected specimen.",
"     </li>",
"     <li>",
"      A second report included 115 patients with locally advanced disease who received low-dose infusional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (12",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day over five consecutive days) concurrent with external beam RT (1.5 to 2 Gy daily), with cycles repeated at two week intervals [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/26\">",
"       26",
"      </a>",
"      ]. Treatment was well tolerated with no grade 3 toxicity. The objective response rate was 67 percent, and 39 responders were able to undergo subsequent surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others have reported success with sequential administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (30 mg total dose daily for three consecutive days) followed by RT (30 Gy in 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/22,27\">",
"     22,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    use concurrent with RT. In a retrospective report of 43 patients, 31 with localized disease, the majority of patients (60 percent) received their first cycle of full-dose ifosfamide-containing chemotherapy during the first week of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/28\">",
"     28",
"    </a>",
"    ]. Sixty percent received two or more cycles (median dose per cycle 10.2 Gm) during RT, while the remainder received only one cycle.",
"   </p>",
"   <p>",
"    Grade 4 systemic toxicity during therapy included leukopenia (n = 14 patients), neurotoxicity (including one patient with suicidal ideation), and diarrhea (n = 1). Approximately 50 percent of patients had &ge;90 percent tumor necrosis, including two with a pathologic complete response, but 23 percent developed major wound complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gemcitabine and temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some more recent efforts focus on concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    during RT for locally advanced primary extremity STS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase I study with a novel trial design reported in abstract form, using expected and observed toxicity to determine whether to escalate the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      dose, a weekly schedule was quickly identified that yielded a fairly substantial rate of necrosis in the surgical specimen of the primary tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/29\">",
"       29",
"      </a>",
"      ]. No confirmatory phase II and III studies utilizing this approach are available.",
"     </li>",
"     <li>",
"      Promising efficacy for preoperative chemoradiotherapy using oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once daily, seven days per week) during intensity modulated RT (IMRT, 50.4 Gy) was suggested in a study of 15 patients with high grade primary (n = 11) or locally recurrent (n = 4) STS not amenable to surgical resection without significant organ or extremity function loss [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/30\">",
"       30",
"      </a>",
"      ]. There were seven extremity STS, seven were truncal, and six were retroperitoneal in location. Ten cases underwent surgery after induction chemoradiotherapy, and nine were resected, seven completely (R0). At a median follow-up of 20 months, only one of the seven undergoing an R0 resection had a tumor recurrence, while one of the two patients who had an R1 resection developed a local and distant recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Multiagent chemotherapy and RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiagent chemotherapy regimens such as AIM (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    ) and MAID (mesna, doxorubicin, ifosfamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , (",
"    <a class=\"graphic graphic_table graphicRef80881 \" href=\"UTD.htm?21/21/21854\">",
"     table 1",
"    </a>",
"    )) provide higher response rates in the metastatic setting than single agent doxorubicin, but they are more toxic, and no trial has demonstrated a survival benefit over single agent therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=see_link\">",
"     \"Treatment protocols for soft tissue and bone sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In theory, the use of a more effective full-dose multiagent chemotherapy regimen in conjunction with RT for nonmetastatic disease has the potential to provide not only a radiosensitizing effect (improved local control), but also early treatment of micrometastatic disease (possibly improving survival).",
"   </p>",
"   <p>",
"    There are no trials that directly compare neoadjuvant chemoradiotherapy using concurrent single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    versus a doxorubicin-based combination regimen. Results are available from two uncontrolled trials of neoadjuvant MAID plus concurrent RT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/24,31\">",
"     24,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial experience with preoperative MAID chemotherapy interdigitated with 44 Gy RT (in two sets of fractions totaling 22 Gy each) and followed by surgery, postoperative MAID, and further RT (16 Gy) for those with positive margins was reported in a series of 48 patients with high-grade primary extremity STS &ge;8 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/24\">",
"       24",
"      </a>",
"      ]. Despite the low objective clinical response to preoperative therapy (partial response in only five patients), the pathologic response rate was high, and all 48 patients were able to undergo limb sparing surgery. Wound healing complications occurred in 29 percent, and 25 percent required hospitalization for febrile neutropenia during treatment. One patient developed late fatal treatment-related myelodysplasia.",
"      <br/>",
"      <br/>",
"      The five year rates of local control (92 percent), freedom from distant metastases (75 percent), disease-free survival (70 percent), and overall survival (87 percent) all compared favorably with the outcomes of a cohort of historical control patients who were matched for tumor size, grade, patient age, and era of treatment. In updated results with a median follow-up of 9.3 years in the surviving MAID patients, the 10-year disease-free and overall survival rates were 65 and 66 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar regimen (although with higher",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      dose, 2500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for three days) was studied in a multicenter United States cooperative group trial (RTOG study 9514) involving 66 patients with primary high-grade STS &ge;8 cm in diameter (median 15 cm) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/31\">",
"       31",
"      </a>",
"      ]. The objective partial response rate was 22 percent by original (version 1.0) RECIST (",
"      <a class=\"graphic graphic_table graphicRef74693 \" href=\"UTD.htm?41/48/42764\">",
"       table 2",
"      </a>",
"      ), but treatment-related toxicity was worse than seen in the prior study. Grade 4 hematologic and nonhematologic toxicity was experienced by 78 and 19 percent of patients, and there were three fatal (grade 5) adverse events (two acute myeloid leukemias, one infection). Seven patients (11 percent) had serious or major postoperative complications that either significantly delayed postoperative chemotherapy (n = 5) or resulted in the need for amputation (n = 2).",
"      <br/>",
"      <br/>",
"      At a median follow-up of 2.75 years, the estimated three-year overall survival, disease-free survival and distant disease-free survival rates were 75, 57, and 65 percent, respectively. The estimated three-year rate of local control was 82 percent if amputation was considered a failure and 90 percent if it was not. Despite the shorter duration of follow-up, these results are not as favorable as reported in the earlier study. In the latest update with a median follow-up of 7.7 years in surviving patients, estimated five-year rates of disease free, distant disease-free, and overall survival were 56, 64, and 71 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies do not provide sufficient support for the routine use of preoperative MAID plus interdigitated RT. A major problem is that treatment-related toxicity can be pronounced. The radiation fields employed in the RTOG 9514 study extended 9 cm proximal and distal to the gross tumor. These are larger than the fields currently in use, which extend 5 cm proximal and distal to gross tumor; even smaller fields (extending 2 to 3 cm proximal and distal to the gross tumor) are being investigated in the recently completed RTOG 0630 study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the authors' opinion, if preoperative treatment with MAID and RT is used, it should employ these smaller fields to reduce toxicity, employ lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    than were used in the RTOG study, and ideally be undertaken in the setting of a clinical trial or by institutions with sufficient experience with these regimens to minimize potential toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Response assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;These studies also illustrate the problem of response assessment. In many of these studies, tumor size did not change much by examination or imaging after neoadjuvant therapy, while the degree of necrosis was substantial on histologic review of the surgical specimen. This finding, which is observed repeatedly in the treatment of sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], refutes the utility of objective measures of disease response such as the RECIST (Response Evaluation Criteria in Solid Tumors (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"UTD.htm?41/48/42764\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]) or WHO criteria as the sole indicator of a clinical response.",
"   </p>",
"   <p>",
"    The clinical importance of noninvasively determining histologic response is unclear. There are conflicting data on whether higher degrees of histologic necrosis predict better outcomes in soft tissue sarcomas (as they do in patients undergoing neoadjuvant treatment for bone sarcomas) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Furthermore, as in bone sarcomas, there is no evidence to suggest benefit from altering treatment in a patient who has a poor histologic response to initial neoadjuvant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=see_link&amp;anchor=H7#H7\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Tailored postoperative chemotherapy based upon initial response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, at least some data suggest that a reduction in glucose metabolic activity may be more accurate than size change at predicting the histopathologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Early determination of treatment response, as with PET scanning, might allow individuals with a good response to treatment continue the same regimen, while those without a good response could switch over to an alternative treatment strategy. Other new imaging modalities using alternative nuclear medicine tracers or dynamic contrast MRI may also contribute to response assessment in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Previously irradiated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding local therapy are more difficult in patients who underwent RT as a component of primary treatment. For these patients, options include wide or radical resection, marginal limb sparing surgery plus reirradiation, and where available and appropriate, systemic chemotherapy with regional hyperthermia or regional chemotherapy. Amputation is also at times an option that restores function while eradicating the local recurrence. Amputation should not always be viewed as a failure, when at times it offers good function while avoiding the potential side effects of some of the adjuvant therapies. Some patients may chose this option if it means extending survival and offers reasonable function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Reirradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials testing the benefits and risks of reirradiation in patients with a recurrent tumor who underwent RT as a component of primary treatment. An additional course of external beam RT may exceed the maximal tolerance for adjacent normal tissues, resulting in problems in wound healing and radiation fibrosis. In a series of 14 patients undergoing reirradiation (predominantly with external beam RT) for recurrent STS of the extremity or trunk after gross total resection, one-half had serious complications requiring reoperation or leading to permanent functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, additional radiation doses can often be safely administered using brachytherapy techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/12,45,46\">",
"     12,45,46",
"    </a>",
"    ]. The success of this approach can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report detailed the outcome of salvage therapy in 23 patients with an isolated locally recurrent STS after limb sparing surgery and RT [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/12\">",
"       12",
"      </a>",
"      ]. Seven patients had an amputation, while 16 underwent another limb sparing resection without (n = 11) or with (n = 5) reirradiation. Seven of the 11 who did not undergo additional RT after surgery had a second relapse, five of whom were subsequently treated by limb sparing reresection and reirradiation.",
"      <br/>",
"      <br/>",
"      Of the 10 reirradiated patients, brachytherapy alone was administered to six, brachytherapy plus external beam RT in one, and three received external beam RT alone. The median radiation dose at the time of retreatment was 49.5 Gy, and the median cumulative soft tissue dose was 100 Gy. None of these patients treated with surgery plus reirradiation relapsed with a median follow-up of 24 months. Six (60 percent) experienced significant wound healing complications, but three recovered completely.",
"     </li>",
"     <li>",
"      In another series, 26 patients with a STS recurrence in a previously irradiated field underwent margin-negative reresection and perioperative brachytherapy (47.2 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/45\">",
"       45",
"      </a>",
"      ]. With a median follow-up of 16 months, the estimated five-year local control and disease-free survival rates were 52 and 33 percent, respectively. Complications developed in five patients; three had wound breakdown, one had osteonecrosis, and one had neuralgia. Operative intervention was required in four.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others have questioned the benefit of reirradiation in patients for whom a wide local excision is possible. A review of the M. D. Anderson experience included 62 patients who had a sarcoma recurrence in an irradiated field [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/46\">",
"     46",
"    </a>",
"    ]. Treatment consisted of wide local excision (WLE) alone (n = 25), or with reirradiation (n = 37, brachytherapy alone in 33). Local control rates were higher in the reirradiated group (39 versus 58 percent), but there were no differences in five-year disease-specific survival (67 versus 66 percent) or distant metastasis-free survival.",
"   </p>",
"   <p>",
"    Interpretation of these results is limited by imbalances in the two groups in terms of histopathologic subtype, grade of differentiation, and tumor site, the high incidence of positive resection margins in both groups (14 of 25 versus 12 of 37 in the WLE and reirradiation groups, respectively) and the high rates of major wound complications after reirradiation (57 percent). These rates are higher than those reported by others (approximately 13 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Regional chemotherapy approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Where available, tumor necrosis factor (TNF)-based isolated limb perfusion (ILP) can avoid amputation in most patients with recurrent extremity STS in a prior irradiated field. These therapies are not available in the United States.",
"   </p>",
"   <p>",
"    One report detailed outcomes of ILP in 26 patients who were felt to require amputation for a locally recurrent STS in a previously irradiated field; four required two separate ILP treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/48\">",
"     48",
"    </a>",
"    ]. There were six complete and 15 partial responses (objective response rate 70 percent), and limb salvage was achieved in 17 (65 percent). At a median follow-up of 22 months, the local recurrence rate was higher in those with multiple as compared to single tumors (45 versus 27 percent). Ten patients (35 percent) died of systemic metastases, and remainder remained alive at last follow-up.",
"   </p>",
"   <p>",
"    A description of the ILP procedure, and additional data on the outcomes of ILP (which has most often been performed for patients with a primary unresectable extremity STS) are provided below. The availability of ILP utilizing TNF is limited to specialized centers outside of the US; TNF is not available anywhere in the US. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Isolated limb perfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Comparable efficacy with less toxicity has been reported with an alternative type of regional chemotherapy treatment called isolated limb infusion (ILI). However, as with ILP, the availability of ILI is limited to specialized centers. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Isolated limb infusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chemotherapy with regional hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy combined with regional hyperthermia may represent another potentially limb-sparing technique for patients with a locally recurrent tumor in an irradiated field. This technique is not widely available in the US. A randomized study from the EORTC (study 62961), reported only in abstract form, showed better local control for regional hyperthermia plus chemotherapy versus chemotherapy alone for those patients with highest risk of local recurrence. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Systemic chemotherapy with and without regional hyperthermia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is an important component of successful therapy for locally recurrent STS. As with primary treatment, the goal is to salvage the limb with a complete resection and wide margins. This is not always possible. For previously unirradiated patients, combined modality therapy is indicated to improve rates of local control. There are no randomized trials proving benefit of chemoradiotherapy over preoperative RT alone, and institutional practice varies. At many institutions, RT alone represents the most commonly used strategy for patients with large (&ge;8 cm) high-grade primary or locally recurrent STS of the extremity. Other approaches, such as sequential or interdigitated single agent or multiagent chemotherapy plus RT, are reasonable options provided that institutions have gained the necessary experience to manage these complicated treatments. The particular approach chosen should be based upon institutional expertise, experience, and preferences.",
"   </p>",
"   <p>",
"    Local control with limb preserving resection alone may be unsuccessful, and the decision for local therapy in previously irradiated patients is difficult. Options are wide local excision (if possible), reirradiation, amputation, and where available, regional chemotherapy or systemic chemotherapy with regional hyperthermia. This decision must be individualized based upon the location and size of the tumor recurrence, institutional expertise, and the wishes of a well-informed patient. Potential risks of reirradiation in this setting include wound healing problems, osteonecrosis, nerve damage, fibrosis, poor functional outcome, need for reoperation, and amputation.",
"   </p>",
"   <p>",
"    The role of postoperative adjuvant chemotherapy is undefined. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     UNRESECTABLE LOCALLY ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with advanced STS in whom the tumor has progressed beyond surgical resectability, treatment options depend upon the site of tumor involvement, and the treating center. There are no randomized phase III trials to define the most effective option, and treatment strategies vary widely between different countries and expert centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Radiation therapy and chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least in the US, most patients are offered RT with or without concomitant chemoradiotherapy. Selected patients can achieve local control with external beam RT with or without chemotherapy, especially if the tumor is small [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perhaps more importantly, a response to RT and chemotherapy may convert an initially unresectable tumor to one that can be resected and potentially cured. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Preoperative chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Regional chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unresectable disease limited to the extremity, regional chemotherapy has been applied with marked early success. Two techniques are available, isolated limb perfusion and Isolated limb infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Isolated limb perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated limb perfusion (ILP) involves surgical isolation of the vascular inflow and outflow of an extremity to separate the circulation of the affected limb from that of the remainder of the body. Thus, high concentrations of drugs can be circulated locally without exposing the rest of the body to the same level of toxicity. By excluding the liver and kidney from the perfusion circuit, drug metabolism is minimized, thus leading to sustained high concentrations of drug in the perfused limb. The isolated extremity is usually subjected to mild hyperthermia (target tissue temperature between 38.5&ordm;C and 40&ordm;C) to improve antitumor effect without subjecting the entire body to the risks of hyperthermia.",
"   </p>",
"   <p>",
"    Hyperthermic ILP is performed under general anesthesia. ILP of the lower extremities is most commonly performed via cannulation of the external iliac vessels; the axillary vessels are used in the arm. However, ILP can be performed via the femoral or popliteal vessels in the lower extremity, and via the brachial vessels in the arm in certain clinical situations. The vessels are cannulated and connected to the inflow and outflow lines of an extracorporeal bypass circuit identical to that used in cardiac surgery. A tourniquet is applied around the root of the extremity to occlude superficial veins that could communicate between the limb circuit and the remainder of the body.",
"   </p>",
"   <p>",
"    Further details of the procedure are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=see_link&amp;anchor=H13#H13\">",
"     \"Cutaneous melanoma: Management of in transit metastases\", section on 'Perfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies of ILP for locally advanced STS have utilized high dose tumor necrosis factor-alpha (TNF-alpha) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    with or without interferon. Recombinant TNF-alpha is a highly potent antineoplastic agent, but systemic administration in humans results in a life-threatening septic shock-like syndrome. The regional administration of TNF-alpha via ILP eliminates systemic side effects and permits the delivery of a TNF dose that is 10-fold higher than the maximally tolerated systemic dose. Systemic toxicity is generally moderate and includes fever, chills, and a hyperdynamic circulatory state. Toxicity seems to be reduced and efficacy maintained with lower doses of TNF-alpha (1 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute treatment-related toxicity was addressed in a report of 88 patients, in which acute regional toxicity was mild (grade 1 to 2, corresponding to either no toxicity or mild erythema or edema) in 86 percent, more severe (grade 3, with considerable",
"    <span class=\"nowrap\">",
"     erythema/edema",
"    </span>",
"    with slight blistering, with or without impairment of mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/52\">",
"     52",
"    </a>",
"    ]) in 10 percent, and grade 4 (extensive epidermolysis or obvious damage to the deep tissues, causing definite impairment; threatening or manifest compartment syndrome) in 3 percent. There were no grade 5 toxicities (reaction requiring amputation).",
"   </p>",
"   <p>",
"    Several studies report encouraging results with TNF-alpha-based ILP for unresectable extremity STS (",
"    <a class=\"graphic graphic_table graphicRef76912 \" href=\"UTD.htm?17/46/18158\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/48,51,53-69\">",
"     48,51,53-69",
"    </a>",
"    ]. Follow-up in nearly all of these series is limited to two years or less (and most of the data on long-term outcomes are from actuarial estimates, with one exception). Long-term outcomes were addressed in a Dutch cohort of 208 patients who were treated with TNF-alpha-based ILP for locally advanced (n = 134) or locally recurrent (n = 97) extremity soft tissue sarcoma; the median follow-up duration was 12 years, range 5 to 19 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/70\">",
"     70",
"    </a>",
"    ]. Overall, the limb salvage rate was 81 percent, 30 percent had a local recurrence, and 5 and 10-year overall survival rates were 42 and 33 percent, respectively.",
"   </p>",
"   <p>",
"    These results support the view that ILP appears to provide the opportunity to salvage limbs that might otherwise require amputation because of a locally advanced or recurrent tumor. However, the quality of the available studies is limited, with significant methodological heterogeneity, and a lack of uniformity in defining potential candidates and response outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/71\">",
"     71",
"    </a>",
"    ]. Furthermore, ILP with TNF-alpha and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    is a complex and time-consuming procedure, and expertise in this technique is not widely available except in selected centers in Europe where the procedure has received regulatory approval. There is no access to TNF in the United States. It should also be acknowledged that there is limited data on the function of the limb and quality of life in patients treated by ILP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Isolated limb infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative type of regional chemotherapy treatment is isolated limb infusion (ILI), which was developed at the Sydney Melanoma Unit for treatment of locoregionally advanced melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=see_link&amp;anchor=H14#H14\">",
"     \"Cutaneous melanoma: Management of in transit metastases\", section on 'Infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The artery and vein of an extremity are accessed percutaneously using high flow catheters, and a pneumatic tourniquet is used proximally to isolate the extremity (",
"    <a class=\"graphic graphic_figure graphicRef65340 \" href=\"UTD.htm?17/9/17558\">",
"     figure 1",
"    </a>",
"    ). ILI differs from isolated limb perfusion (ILP) in that it circulates blood in the isolated extremity at a much slower rate than ILP and for only 30 minutes. During ILI the extremity is hypoxic, which leads to marked acidosis. In contrast, with hyperthermic ILP, the pump oxygenator maintains oxygenation and normal",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    status of the extremity. In addition, ILI also uses standard chemotherapy drugs and not tumor necrosis factor (TNF).",
"   </p>",
"   <p>",
"    The safety and efficacy of ILI for locally advanced unresectable extremity STS has been addressed in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review included 21 patients with locally advanced extremity STS treated at a single institution with ILI using high-dose chemotherapy (mainly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/72\">",
"       72",
"      </a>",
"      ]. Fourteen received ILI prior to definitive surgery; seven had either an inoperable recurrence or metastatic disease.",
"      <br/>",
"      <br/>",
"      Twelve patients had a complete response to therapy, seven had a partial response, and two had no response, for an overall response rate of 90 percent. Nine of the 14 patients treated preoperatively (65 percent) had a pathologic complete response. At a median follow-up of 28 months, there were nine local recurrences (42 percent), and the overall disease-specific survival was 62 percent. Only five patients ultimately required limb amputation for disease progression.",
"     </li>",
"     <li>",
"      A second report included 40 patients undergoing preoperative ILI using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus external beam RT for an extremity STS for which amputation was felt to be the only available treatment option [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/73\">",
"       73",
"      </a>",
"      ]. All patients had a single course of ILI with doxorubicin (0.7 and 1.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for the upper and lower limbs, respectively), followed three to seven days later by preoperative external beam RT (35 Gy in 10 fractions); surgery was performed three to seven weeks later.",
"      <br/>",
"      <br/>",
"      Local morbidity was limited to slight edema or erythema (grade 2 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/52\">",
"       52",
"      </a>",
"      ]) in eight patients, considerable erythema or edema with some blistering and slightly disturbed mobility (grade 3 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/52\">",
"       52",
"      </a>",
"      ]) in four, and no more serious toxicity. A tumor response was seen in 85 percent, rendering most patients resectable. At a median follow-up of 15 months, limb salvage was achieved in 83 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although randomized trials have not been carried out, these reports, combined with the experience in locoregionally advanced melanoma, suggest that ILI provides a comparable degree of antitumor efficacy as ILP with less toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=see_link&amp;anchor=H14#H14\">",
"     \"Cutaneous melanoma: Management of in transit metastases\", section on 'Infusion'",
"    </a>",
"    .) Neither of these studies looked at function of the salvaged limb to determine if the quality of life was comparable or superior to amputation. Five of 12 in the first study and 17 percent of the second study ultimately resulted in amputation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;While these data seem encouraging, regional chemotherapy approaches are not widely used within the United States, given the labor-intensive nature of the procedures. It is not clear for whom these techniques represent optimal therapy and especially whether there are any advantages to ILP or ILI as compared to radiation therapy with or without chemotherapy in patients who are either not resectable without amputation or truly unresectable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Systemic chemotherapy with and without regional hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of induction chemotherapy alone is uncertain. Adequately powered, randomized phase III trials are not available, and the results of uncontrolled studies are conflicting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link&amp;anchor=H15#H15\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, at least some data from Europe suggest that systemic chemotherapy combined with regional hyperthermia may represent an alternative potentially limb-sparing technique for patients with locally advanced unresectable high-grade STS of the extremities and trunk, as well as those with a locally recurrent tumor in an irradiated field [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/74-77\">",
"     74-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefit for this approach was suggested in a trial (EORTC study 62961) in which 341 patients with locally recurrent (n = 37), incompletely resected or resected with a surgical margin &lt;1 cm (n = 142), or grade 2 or 3 primary STS &ge;5 cm (n = 162) of the extremity (43 percent) or non-extremity site (pelvis, abdomen, trunk, head and neck) were randomly assigned to four courses of systemic chemotherapy with or without regional hyperthermia, followed by aggressive local therapy (surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT) and four additional courses of chemotherapy with or without regional hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/76\">",
"     76",
"    </a>",
"    ]. Chemotherapy consisted of 21-day cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 4),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (1500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day on days 1 through 4), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 only), while regional hyperthermia was performed by exposing the affected body part to temperatures between 40 and 43 degrees for 60 minutes on days 1 and 4 of each chemotherapy course.",
"   </p>",
"   <p>",
"    The objective response rate from preoperative chemotherapy was significantly higher in the hyperthermia group (29 versus 13 percent), although the number of patients who had definitive tumor resection as a component of local treatment was similar (two-thirds of both groups), as were amputation rates (5 versus 6 percent). At a median follow-up of 34 months, disease-free survival (median 32 versus 18 months), and two-year local progression-free survival (76 versus 61 percent) significantly favored the regional hyperthermia arm. However, the trial was heavily weighted towards retroperitoneal sarcomas, which have a higher local recurrence rate than do extremity sarcomas. In fact, the higher rate of two-year local progression-free survival with hyperthermia was significant in those with non-extremity primary tumors (64 versus 45 percent, p = 0.012) but not in those with an extremity sarcoma (92 versus 80 percent, p = 0.20).",
"   </p>",
"   <p>",
"    Overall survival was not significantly better in the hyperthermia group when all patients were analyzed (at four years, 59 versus 57 percent), but in the 269 patients who completed the full treatment, those who received hyperthermia were 44 percent less likely to die during follow-up that those assigned to chemotherapy alone.",
"   </p>",
"   <p>",
"    Quality assurance guidelines for regional hyperthermia are available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/78\">",
"     78",
"    </a>",
"    ]. Although not used much in the US, regional hyperthermia with systemic chemotherapy is an option for high-risk extremity tumors in other parts of the world where it is available. Whether this approach is superior to ILP with low-dose TNF alpha and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , ILI, or radiotherapy with or without chemotherapy will require a randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Palliative chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cases that are not amenable to local therapy, palliative systemic chemotherapy remains an option for treatment of locally advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Summary and NCCN guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with advanced STS in whom the tumor has progressed beyond surgical resectability, treatment options depend upon the site of tumor involvement, and the treating center. There are no randomized phase III trials to define the most effective option, and treatment strategies vary widely between different countries and expert centers. In the US, most patients are offered RT rather than concurrent chemoradiotherapy, although sequential and interdigitated chemoradiotherapy approaches have also been employed. The particular approach chosen should be based upon institutional expertise, experience and preferences. In some cases, an initially unresectable tumor may be converted to one that is potentially resectable for cure.",
"   </p>",
"   <p>",
"    Where available, ILP, ILI, and systemic chemotherapy with regional hyperthermia represent alternative potentially limb sparing treatments. None of these approaches is widely available in the US. Further, it is not clear for whom these techniques represent optimal therapy and especially whether there are any advantages as compared to radiation therapy with or without chemotherapy in patients who are either not resectable without amputation or truly unresectable. In certain cases, especially with more distal tumors and in younger, healthier patients, amputation may offer reasonable function, quality of life and local tumor control.",
"   </p>",
"   <p>",
"    Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) for management of patients with locally advanced unresectable extremity STS include initial RT, chemotherapy, or chemoradiotherapy, with surgical resection if the patient becomes resectable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/79\">",
"     79",
"    </a>",
"    ]. If neoadjuvant chemotherapy is chosen, we generally prefer the AIM regimen (",
"    <a class=\"graphic graphic_table graphicRef67985 \" href=\"UTD.htm?40/20/41294\">",
"     table 4",
"    </a>",
"    ) or MAID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=see_link\">",
"     \"Treatment protocols for soft tissue and bone sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who remain unresectable after neoadjuvant therapy, options include definitive RT (in patients who have not had a prior course of irradiation), chemotherapy, palliative surgery, observation (for an asymptomatic patient), or best supportive care. The guidelines do not address the use of ILP, ILI, or chemotherapy with regional hyperthermia.",
"   </p>",
"   <p>",
"    The role of postoperative adjuvant chemotherapy after best local therapy is undefined. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main purpose of posttreatment surveillance is the detection of local recurrences and pulmonary metastases. Isolated limited metastatic tumor to the lung is potentially resectable for cure and is frequently asymptomatic.",
"   </p>",
"   <p>",
"    We recommend frequent follow-up, particularly in the first two years after treatment, given that two-thirds of recurrences will be detected during this period. One exception to this general rule is that synovial sarcomas tend to grow slowly, and they are associated with a high incidence of late metastases, even after 10 years. In one series, the mean metastasis-free survival was 11 years (range 0.5 to 28 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/80\">",
"     80",
"    </a>",
"    ]. Patients who experience a local recurrence of their tumor also appear to be at higher risk for late metastases, even if they are otherwise at low risk for metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although posttreatment surveillance guidelines have not been established through rigorous clinical investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/82\">",
"     82",
"    </a>",
"    ], we follow patients with a history, physical examination and chest radiograph at three to four month intervals for the first two years, four to six month intervals for the next three years, and yearly thereafter.",
"   </p>",
"   <p>",
"    We also perform imaging studies (CT scans of the chest and, for those patients at higher risk of local recurrence such as those with positive margins or those whose primary tumor site is not easily examined (either because of location or posttreatment",
"    <span class=\"nowrap\">",
"     fibrosis/scarring),",
"    </span>",
"    MRI imaging of the primary site) at four to six month intervals for the first two years and then yearly out to five years.",
"   </p>",
"   <p>",
"    Consensus-based surveillance guidelines after treatment of an extremity sarcoma from the National Comprehensive Cancer Network (NCCN) include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/45/27354/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I disease (",
"      <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"       table 5",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History and physical examination every three to six months for two to three years, then annually.",
"     </li>",
"     <li>",
"      &ldquo;Consider&rdquo; chest imaging every 6 to 12 months.",
"     </li>",
"     <li>",
"      Periodic imaging of the primary site, based on estimated risk of locoregional recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage II, III (and IV) disease (",
"      <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"       table 5",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History and physical examination and chest imaging every three to six months for two to three years, then every six months for the next two years, then annually.",
"     </li>",
"     <li>",
"      Periodic imaging of the primary site, based on estimated risk of locoregional recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, we follow these guidelines.",
"   </p>",
"   <p>",
"    We reexamine or reimage the primary site at four to six month intervals for the first two years and then yearly out to five years. Local control rates for patients who have undergone wide resection alone with good margins or conservative surgery with negative margins plus RT are 92 to 95 percent. For these patients, we favor baseline posttreatment imaging, but a heavier reliance on physical examination in those whose primary sites are amenable to examination. For those patients at higher risk of local recurrence, such as those with positive margins, as well as those whose primary tumor site is not easily examined (either because of location or treatment-related",
"    <span class=\"nowrap\">",
"     fibrosis/scarring),",
"    </span>",
"    the preferred approach is periodic imaging with MRI of the primary site.",
"   </p>",
"   <p>",
"    When planning the posttreatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas are rare malignant tumors that arise from extraskeletal connective tissues at any body site. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because of their rarity and the frequent need for multimodality treatment, evaluation and management of soft tissue sarcomas should ideally be carried out in a center with expertise in the treatment of sarcomas, including surgical, orthopedic, medical, pediatric, and radiation oncology. (See",
"    <a class=\"local\" href=\"#H7794442\">",
"     'Importance of multidisciplinary evaluation and management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In treating both primary and recurrent STS of the extremities, the major therapeutic goals are survival, avoidance of a local recurrence, maximizing function, and minimizing morbidity. There are a wide variety of clinical situations that arise from involvement of a variety of different anatomic sites, the range of histologies, and variability in grade and tumor size. As a result, for most patients, treatment must be individualized. The following suggestions can serve as a useful guide to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Local recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a locally recurrent STS, we recommend reresection rather than nonoperative therapy, if possible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Reresection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In addition to limb sparing surgery, we recommend external beam RT for patients who have not previously been irradiated (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In this setting, we suggest preoperative rather than postoperative RT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adjunctive RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest RT rather than chemoradiotherapy for most patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), but there is no consensus on this issue and institutional practice varies. Other approaches, such as sequential or interdigitated single agent or multiagent chemotherapy plus RT, are reasonable options provided that institutions have gained the necessary experience to manage these complicated treatments. The particular approach chosen should be based upon institutional expertise, experience and preferences. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision as to optimal local therapy is more difficult in previously irradiated patients. Options include wide local excision alone, limb sparing surgery with brachytherapy, amputation, or, where available, regional chemotherapy or systemic chemotherapy plus regional hyperthermia. This decision must be individualized based upon the location and size of the tumor recurrence, institutional expertise, and the wishes of a well-informed patient. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Previously irradiated patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Unresectable locally advanced",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with advanced STS in whom the tumor has progressed beyond surgical resectability, treatment options depend upon the site of tumor involvement, and the treating center. There are no randomized phase III trials to define the most effective option, and treatment strategies vary widely between different countries and expert centers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We encourage patients to enroll on a clinical trial testing new strategies.",
"     </li>",
"     <li>",
"      If trial participation is not feasible, we suggest chemoradiotherapy rather than radiotherapy alone for most patients with intermediate or high grade tumors larger than 8 cm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For some initially unresectable tumors, there may be a sufficient response to permit later limb-sparing surgery. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Radiation therapy and chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where available, isolated limb perfusion (ILP) with low-dose TNF alpha plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and isolated limb infusion (ILI) represent potentially limb-preserving options, but expertise is limited, and these procedures are not in widespread use in the US. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Regional chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although not used much in the US, regional hyperthermia with systemic chemotherapy is another potentially limb-preserving option for high-risk extremity and truncal tumors in other parts of the world where it is available. Whether this approach is superior to ILP or ILI or radiotherapy alone or chemoradiotherapy will require a randomized trial. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Chemotherapy with regional hyperthermia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In certain cases, amputation with modern prosthetic fitting, especially in the lower extremity, may be the most reasonable option.",
"     </li>",
"     <li>",
"      For cases that are not amenable to local therapy, palliative systemic chemotherapy remains an option for treatment of locally advanced disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link\">",
"       \"Systemic treatment of metastatic soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7684459\">",
"    <span class=\"h2\">",
"     Posttreatment follow-up",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following treatment of stage II or III or recurrent disease, we suggest a history and physical examination and chest imaging at three to six month intervals for the first two years, at four to six month intervals for the next three years, and yearly thereafter. For stage I disease, we suggest a history and physical examination every three to six months for two to three years, then annually.",
"      <br/>",
"      <br/>",
"      For all patients, we examine or image the primary site at four to six month intervals for the first two years and then yearly out to five years. For those patients at higher risk of local recurrence, such as those with positive margins as well as those whose primary tumor site is not easily examined or complicated by posttreatment fibrosis or scarring, periodic imaging of the primary site with MRI is the preferred method of assessing the primary site. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H32#H32\">",
"       \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Posttreatment cancer surveillance'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/1\">",
"      LeVay J, O'Sullivan B, Catton C, et al. Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys 1993; 27:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/2\">",
"      Karakousis CP, Driscoll DL. Treatment and local control of primary extremity soft tissue sarcomas. J Surg Oncol 1999; 71:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/3\">",
"      Sadoski C, Suit HD, Rosenberg A, et al. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993; 52:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/4\">",
"      Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/5\">",
"      Gronchi A, Miceli R, Fiore M, et al. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann Surg Oncol 2007; 14:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/6\">",
"      Eilber FC, Rosen G, Nelson SD, et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 2003; 237:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/7\">",
"      Singer S, Corson JM, Gonin R, et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994; 219:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/8\">",
"      Lewis JJ, Leung D, Heslin M, et al. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 1997; 15:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/9\">",
"      Trovik CS, Gustafson P, Bauer HC, et al. Consequences of local recurrence of soft tissue sarcoma: 205 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand 2000; 71:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/10\">",
"      Ramanathan RC, A'Hern R, Fisher C, Thomas JM. Prognostic index for extremity soft tissue sarcomas with isolated local recurrence. Ann Surg Oncol 2001; 8:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/11\">",
"      Eilber FC, Brennan MF, Riedel E, et al. Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas. Ann Surg Oncol 2005; 12:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/12\">",
"      Catton C, Davis A, Bell R, et al. Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy. Radiother Oncol 1996; 41:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/13\">",
"      Karakousis CP, Proimakis C, Rao U, et al. Local recurrence and survival in soft-tissue sarcomas. Ann Surg Oncol 1996; 3:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/14\">",
"      Ueda T, Yoshikawa H, Mori S, et al. Influence of local recurrence on the prognosis of soft-tissue sarcomas. J Bone Joint Surg Br 1997; 79:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/15\">",
"      Eilber FR, Morton DL, Eckardt J, et al. Limb salvage for skeletal and soft tissue sarcomas. Multidisciplinary preoperative therapy. Cancer 1984; 53:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/16\">",
"      Engel CJ, Eilber FR, Rosen G, et al. Preoperative chemotherapy for soft tissue sarcomas of the extremities: the experience at the University of California, Los Angeles. Cancer Treat Res 1993; 67:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/17\">",
"      Soulen MC, Weissmann JR, Sullivan KL, et al. Intraarterial chemotherapy with limb-sparing resection of large soft-tissue sarcomas of the extremities. J Vasc Interv Radiol 1992; 3:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/18\">",
"      Wanebo HJ, Temple WJ, Popp MB, et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer 1995; 75:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/19\">",
"      Levine EA, Trippon M, Das Gupta TK. Preoperative multimodality treatment for soft tissue sarcomas. Cancer 1993; 71:3685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/20\">",
"      Rah&oacute;ty P, K&oacute;nya A. Results of preoperative neoadjuvant chemotherapy and surgery in the management of patients with soft tissue sarcoma. Eur J Surg Oncol 1993; 19:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/21\">",
"      Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994; 73:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/22\">",
"      Temple CL, Ross DC, Magi E, et al. Preoperative chemoradiation and flap reconstruction provide high local control and low wound complication rates for patients undergoing limb salvage surgery for upper extremity tumors. J Surg Oncol 2007; 95:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/23\">",
"      Eilber FR, Giuliano AE, Huth JF, Weisenburger TH, Eckhardt J. Intravenous (IV) vs. intraarterial (IA) Adriamycin, radiation and surgical excision for extremity soft tissue sarcomas: a randomized prospective trial (abstract). Proc Am Soc Clin Oncol 1990; 9:309a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/24\">",
"      DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003; 56:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/25\">",
"      Pisters PW, Patel SR, Prieto VG, et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol 2004; 22:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/26\">",
"      Toma S, Canavese G, Grimaldi A, et al. Concomitant chemo-radiotherapy in the treatment of locally advanced and/or metastatic soft tissue sarcomas: experience of the National Cancer Institute of Genoa. Oncol Rep 2003; 10:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/27\">",
"      Mack LA, Crowe PJ, Yang JL, et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol 2005; 12:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/28\">",
"      Cormier JN, Patel SR, Herzog CE, et al. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. Cancer 2001; 92:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/29\">",
"      Pisters PW, Ballo MT, Bekele N, et al. Phase I trial using toxicity severity weights for dose finding of gemcitabine combined with radiation therapy and subsequent surgery for patients with extremity and trunk soft tissue sarcomas (abstract). J Clin Oncol 2004; 22:820s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/30\">",
"      Jakob J, Wenz F, Dinter DJ, et al. Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009; 75:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/31\">",
"      Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006; 24:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/32\">",
"      Mullen JT, Kobayashi W, Wang JJ, et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer 2012; 118:3758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/33\">",
"      Kraybill WG, Harris J, Spiro IJ, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer 2010; 116:4613.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cancer.gov/clinicaltrials/RTOG-0630 (Accessed on April 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/35\">",
"      Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006; 98:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/36\">",
"      Canter RJ, Martinez SR, Tamurian RM, et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol 2010; 17:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/37\">",
"      Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/38\">",
"      Therasse P, Le Cesne A, Van Glabbeke M, et al. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 2005; 41:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/39\">",
"      Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/40\">",
"      Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19:3203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/41\">",
"      Lucas DR, Kshirsagar MP, Biermann JS, et al. Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation. Oncologist 2008; 13:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/42\">",
"      Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008; 14:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/43\">",
"      Benz MR, Czernin J, Allen-Auerbach MS, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009; 15:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/44\">",
"      Indelicato DJ, Meadows K, Gibbs CP Jr, et al. Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009; 73:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/45\">",
"      Pearlstone DB, Janjan NA, Feig BW, et al. Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field. Cancer J Sci Am 1999; 5:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/46\">",
"      Torres MA, Ballo MT, Butler CE, et al. Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. Int J Radiat Oncol Biol Phys 2007; 67:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/47\">",
"      Nori D, Schupak K, Shiu MH, et al. Role of brachytherapy in recurrent extremity sarcoma in patients treated with prior surgery and irradiation. Int J Radiat Oncol Biol Phys 1991; 20:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/48\">",
"      Lans TE, Gr&uuml;nhagen DJ, de Wilt JH, et al. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 2005; 12:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/49\">",
"      Tepper JE, Suit HD. Radiation therapy alone for sarcoma of soft tissue. Cancer 1985; 56:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/50\">",
"      Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005; 63:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/51\">",
"      Gr&uuml;nhagen DJ, de Wilt JH, van Geel AN, et al. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 2005; 31:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/52\">",
"      Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/53\">",
"      Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a &gt;90% response rate and limb preservation. Cancer 1997; 79:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/54\">",
"      Eggermont AM, Schraffordt Koops H, Li&eacute;nard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/55\">",
"      Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 2003; 98:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/56\">",
"      Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006; 106:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/57\">",
"      Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 2005; 16:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/58\">",
"      Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/59\">",
"      Olieman AF, Pras E, van Ginkel RJ, et al. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998; 40:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/60\">",
"      Gr&uuml;nhagen DJ, Brunstein F, Graveland WJ, et al. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol 2005; 12:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/61\">",
"      Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007; 14:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/62\">",
"      Bonvalot S, Rimareix F, Causeret S, et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 2009; 16:3350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/63\">",
"      Pennacchioli E, Deraco M, Mariani L, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol 2007; 14:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/64\">",
"      van Ginkel RJ, Thijssens KM, Pras E, et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol 2007; 14:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/65\">",
"      Eggermont AM, Schraffordt Koops H, Klaase JM, et al. Limb salvage by isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients (abstract). Proc Am Soc Clin Oncol 1999; 11:535a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/66\">",
"      Lejeune FJ, Pujol N, Li&eacute;nard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000; 26:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/67\">",
"      Deroose JP, van Geel AN, Burger JW, et al. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol 2012; 105:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/68\">",
"      Olofsson R, Bergh P, Berlin O, et al. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2012; 19:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/69\">",
"      Di Filippo F, Giacomini P, Rossi CR, et al. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). In Vivo 2009; 23:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/70\">",
"      Deroose JP, Eggermont AM, van Geel AN, et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011; 29:4036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/71\">",
"      Trabulsi NH, Patakfalvi L, Nassif MO, et al. Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol 2012; 106:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/72\">",
"      Moncrieff MD, Kroon HM, Kam PC, et al. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2008; 15:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/73\">",
"      Hegazy MA, Kotb SZ, Sakr H, et al. Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007; 14:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/74\">",
"      Issels RD, Abdel-Rahman S, Wendtner C, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 2001; 37:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/75\">",
"      Wendtner CM, Abdel-Rahman S, Krych M, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002; 20:3156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/76\">",
"      Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/77\">",
"      Schlemmer M, Wendtner CM, Lindner L, et al. Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS). Int J Hyperthermia 2010; 26:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/78\">",
"      Lagendijk JJ, Van Rhoon GC, Hornsleth SN, et al. ESHO quality assurance guidelines for regional hyperthermia. Int J Hyperthermia 1998; 14:125.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/80\">",
"      Krieg AH, Hefti F, Speth BM, et al. Synovial sarcomas usually metastasize after &gt;5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol 2011; 22:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/81\">",
"      Trovik CS, Bauer HC. Local recurrence of soft tissue sarcoma a risk factor for late metastases. 379 patients followed for 0.5-20 years. Acta Orthop Scand 1994; 65:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/45/27354/abstract/82\">",
"      Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Semin Oncol 2003; 30:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7732 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27354=[""].join("\n");
var outline_f26_45_27354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7794442\">",
"      IMPORTANCE OF MULTIDISCIPLINARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LOCALLY RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Reresection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adjunctive RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preoperative chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gemcitabine and temozolomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Multiagent chemotherapy and RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Response assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Previously irradiated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Reirradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Regional chemotherapy approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chemotherapy with regional hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      UNRESECTABLE LOCALLY ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Radiation therapy and chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Regional chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Isolated limb perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Isolated limb infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Systemic chemotherapy with and without regional hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Palliative chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Summary and NCCN guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Local recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Unresectable locally advanced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7684459\">",
"      Posttreatment follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7732|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/9/17558\" title=\"figure 1\">",
"      Isolated limb infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7732|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/21/21854\" title=\"table 1\">",
"      Combination chemotherapy STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42764\" title=\"table 2\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/46/18158\" title=\"table 3\">",
"      TNF ILP unresect extrem sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/20/41294\" title=\"table 4\">",
"      AIM 75_9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/13/23773\" title=\"table 5\">",
"      2010 TNM staging STS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=related_link\">",
"      Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33146?source=related_link\">",
"      Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=related_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=related_link\">",
"      Treatment protocols for soft tissue and bone sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_45_27355="Long term outcome in RA";
var content_f26_45_27355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Natural history and prognosis of rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        70 percent of joint erosions detectable by x-ray of hands and feet occur in the first two years of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At 20 years, over 60 percent of patients with RA belong to functional class III (significantly impaired, self-caring, using aids, requiring joint replacements or class IV (loss of independence requiring daily care)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Increased incidence of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lymphomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Life-expectancy of RA less than age-sex matched control populations especially in patients with one or more of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polyarticular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systemic extra-articular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Persistent disease activity (high ESR, CRP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Positive rheumatoid factor and circulating immune complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        HLA-DR &beta; chain \"shared epitope\", especially if bialleic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27355=[""].join("\n");
var outline_f26_45_27355=null;
var title_f26_45_27356="Empiric intravenous antibiotic therapy for animal bites";
var content_f26_45_27356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric intravenous antibiotic therapy for animal bites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Adults",
"      </td>",
"      <td class=\"subtitle1\">",
"       Children",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Options for empiric gram-negative and anaerobic coverage include:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"2\">",
"       Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Ampicillin-sulbactam 3 g every six hours",
"      </td>",
"      <td>",
"       50 mg/kg per dose (based on ampicillin component) every six hours*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Piperacillin-tazobactam 4.5 g every eight hours",
"      </td>",
"      <td>",
"       125 mg/kg per dose (based on piperacillin component) every eight hours*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Ticarcillin-clavulanate 3.1 g every four hours",
"      </td>",
"      <td>",
"       50 mg/kg per dose (based on ticarcillin component) every four hours*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        A third generation cephalosporin such as ceftriaxone 1 g IV every 24 hours",
"       </p>",
"       <p>",
"        <strong>",
"         PLUS",
"        </strong>",
"       </p>",
"       <p>",
"        Metronidazole 500 mg IV every eight hours",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        A third generation cephalosporin such as ceftriaxone 100 mg/kg per dose every 24 hours*",
"       </p>",
"       <p>",
"        <strong>",
"         PLUS",
"        </strong>",
"       </p>",
"       <p>",
"        Metronidazole 10 mg/kg per dose every eight hours*",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Alternative empiric regimens include:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       A fluoroquinolone (eg, ciprofloxacin 400 mg IV every 12 hours or levofloxacin 500 mg IV daily)",
"       <strong>",
"        PLUS",
"       </strong>",
"       metronidazole 500 mg IV every eight hours",
"      </td>",
"      <td>",
"       Use fluoroquinolones with caution in children &lt;18 years of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"2\">",
"       Monotherapy with a carbapenem&bull;, such as one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Imipenem-cilastatin 500 mg every six hours",
"      </td>",
"      <td>",
"       25 mg/kg per dose every six hours (maximum 500 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Meropenem 1 g every eight hours",
"      </td>",
"      <td>",
"       20 mg/kg per dose every eight hours (maximum 1 g per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Ertapenem 1 g daily",
"      </td>",
"      <td>",
"       15 mg/kg per dose every 12 hours for children up to 12 years of age (maximum 500 mg per dose)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Maximum pediatric dose: See adult dose.",
"     <br>",
"      &bull; Carbapenems should not be used for patients with history of immediate-type hypersensitivity to beta-lactams.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27356=[""].join("\n");
var outline_f26_45_27356=null;
var title_f26_45_27357="Dietary modification in HTN";
var content_f26_45_27357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of dietary modification in mild hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ability of combined nutritional intervention - weight loss, salt restriction, and avoidance of excess alcohol (squares) - to maintain normotension as compared to a control group without dietary modification (circles) after cessation of previously successful antihypertensive therapy. Hypertension recurred in over 90 percent of control patients but in only 60 percent with dietary modification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Stamler, R, Stamler, J, Grimm, R, et al, JAMA 1987; 257:1484.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27357=[""].join("\n");
var outline_f26_45_27357=null;
var title_f26_45_27358="HHV 6 infants young children";
var content_f26_45_27358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Prevalence of HHV-6 infection in young children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 371px; background-image: url(data:image/gif;base64,R0lGODlh7QFzAdUAAP///4CAgAAAAEBAQMDAwAAzmf8AAHBwcP/w8ODg4CAgIP8QEKCgoPDw8DAwMBBAn9DQ0BAQEICZzPDz+UBms/+goP/AwFBQUMDN5v+AgKCz2f9AQGBgYLCwsP9gYJCQkODm8yBNpmCAv/8wMP/g4NDZ7P/Q0P8gILDA3zBZrHCNxlBzuZCm0/9QUP+wsP9wcP+QkB8shYApXKCjyeDW43B8tWBwr7+dtoCJvO8DCT8mcg8vjwAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADtAXMBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tNUDQwBHdTakg0E3t4NANYBDOGfDQ4C6Qfb7Y0EAvHxBADpA+qgHwLsCgIJ7gARdSPAIF6CDgIuALggIJunAPsA3KOHhECAixgDUAzI8YvFjBc3IuEggAMAiAFOCkjpKUG8AREEiCzyMeMAlh1zbglwE+TM/yIu/alMiRIUBHL9olzUyTTLUigkTQLQx+6AgA+gGBBgyA7K06Zgp3xtAk8oAJcKCPT79ymeApxPxoad20TukntdhTDop4DBLbt0Ax8BzIyw4MMn4T4zjDgw42SPG4eNfIyyZKaWi2W+3HHzMM+cAYIONjpQhtMZTDwxsAEACQsIAFgwkEEK6tRDSLzYsAEGAhK3VYf2qthZaUAGWC8w4MKJBdUZDFgAgMACCSnJNyxvbmL5iBHSZy/YkHw65wkaMNQt3uz4n+QAXLAGYAL8iQpCYJwwsOAFgA0vmLDfCAFuUAECANLXW3z73VcEfPK11oIBMAhhwmvzRVebZBiI8P8ABeox4V4vI/YBoQEtALDACRZMaIIJKFpQQW2skUCeBxXMVht4CETnAoweWMAjESemCB8Rs40gpHRRuNAcNSCwEEIIKoAQF3uFYclIdstZoKNstJHgXQuqZcjklxUYUMEIJwAQ3Qgb7GeeEFwyeeQQsyVHmxT74RcNCisUsAIKUpS4i6F7JHfadTD6J59vwE24AABmTvclAqwZ4B8MtHkJG5G0ZXDdfxRaiCGABowQ2xMunNCdB86UoMIDKbAwARWI5pJrHncKMcICGfz62gkvZLDACJS2xmkLMHwJwIQGXCdmf8HOSakBReT5XXjzgeffEwa6NoIHqx6DXgoPiFD/whW7/qXlIrwVgcBuHqg2L28vxJYgAh5skFq4sm0AqxC64Vvuf60VYUK/vSFgQoIPbyAcExYssCoC3x0sTIcFUKCBFu3aErIy/hbhwQgT/wKCBFNKYOVO70IWsy1+jtGdxgC8sEDKjpTAggQYvGyGBhQUIEKIXYxMi9KgkHCCkmN4sKERFSxQcyIToCBB0SGIIAIFD3QsAtDrelGChylocCsYTMvSNihVb2AtFyREm0TFFRpSggYipNCxCigILcQEGLCgAtgFpLCCBCiUTcUELKCrguNhvA2L5Z/0uEALo3LhwcBJvCoIBls/8MAKLCDtBAYabB1CASFQIEF6TgAq/yihZmDuiu6ZR+dB51jUDTwSGLeAcx0gaKCC3ymooIHgV2Cg9Qp+x65C6msLAYIKU7IAPRm8sxL+JyR4QFu5vlGRAehLIKiqHYWvYLrsqotRgtZfF/Dh4enWf8b4qgAg+VoArN+kimdNQMDOoOABV8EBBCg4XOJEoAHKsQEEpFObGwSICg5+wgLaIQ9/ELiEDCQMCsYiYRlQIILXyQ4F2SOFB00xw0+kSU8LdIIC5+aENF3NDBOgkgVPUUMZziwYIsShCql2Qil0Z2pm2NrujmiMInLCaXrC4Q+RcIInUUFA7BsDCB4wxEy4YIuDoaJm1PgLElTgBeDRExqJUIE2Xf8BYxs4nhdEYIMKNIsT3ZljEawoCkKCojomVJMSHIQFBLTgfWFAwA12kIMWNJA1L3DB8CIRSCcYMg4MuEk3BpCGT46Ch0NoledyyAUEVGBCOsBBuRDggkSeoAUZQKUiMPat9YzCJQ6IgAM6QEo0mJIVANsCDBagSym4ckItqMAMQqAEE1TgZKl6QQU2WQiMhXEJx2wDARwgDgcooJj/YyM0KqZHK1RNkAl8JYoOBIAJPAB3TECkdsaTy3b2oQVN9KUoEhCBcKADnblT5zNK9oXu9PIJz5znwaQ4BTfCMVU4WiIeTubPNEZhHCwZRzkQQQC2QMAvxlRoM24Whvp8k3j/8owmzkBQgO9NwQIZaMF+/OWCjsIhAyfwqRE2A4GYDEABQrAHPkSmUmZIbQwYg+QRIirTJKxABV4ggQt2Y4BbepEOVdNoEjbTDwgMASEKYYhDBHEPeSTEHCnVifDIwK8RDI+q9FQCBh4Qwy9YYJnwXIMLWKmUnmTkJ0KAgAAU0A+FFKUogxiAAwYAk3Q01QrhPMXnzuCBBeJVqAColRkcOodO4sqwGEEsAODhgHEK4BorGQoh0iKEA3CAAwhNaE7meoaqQTOvTpASGkgwrjiYFldqVCwpUUIVAFgFK4MoiTgucJPcPmEcH4CrJy+LjPWpwQXpi4I9/QfVjLmBl+xi/2M/OpCOki5WLWYRBEnkEQAOKEQK6BDAPQpKnI4oUKx0UMEK2HAybpbBm1ggajoigNK9LBalg2gATwaAFQiwJQqslYhM+ssRE/6BpjY1g84A/AWAOoW77zCrFfJrTqlUBCQ8QTExdvgH2b2hal8tA0dPHIqixsMB2v0oByLQDyAnoSYYuQlHKhBQPey1r4K12hmACloRyTgRjA3AASLgYinoIyUMYWNmR9HFP4TgY8btTxnCCrNQbPgk1n1CQVqbDggL1A0lCJoTSuAxABzuCXxG8x/q+AcJpIAOxH0pFwZL4iuFQgEXIAB7uyyFLS9WnTWcQAESpwQJFEA9K1NP0f+egIECSCAQjOTDeOsQ1SpH4bgguzIiChKPCKhYDTXUwKZrKoTZsYACIpgACIpGwVADoGgoAPbafj2owX0tUBIoAdAAQLoyykGVfvDaRu3qBVjHWhRH+cCFcS3rKqCLBQXAKgA2nYLXqet1zSv1qYmtAkH5Od2BIpTfVCACU9N0wIEKcRySuYcSPEDgcBhxKwn0hTFrYoY0FQFNqbluCtSzYwDwtHrkfewCCMFvAKDVxVdQAqNR29Qd/3ce2OkHG+sBx1pAcMPLTQi3yiPOZZhhvWO3aUJhvOIZ//TJ5+3xjgO94hznuK79hk87MJQPKAgBlO0w2MA6wcRso3lkKcv/9QHkpZRaj8IDQiABCQRqwD/HuKeBxvGiFc7e+fa0rcaOgXqf2p76ywNLVX1mP5DWCjvO+jQ8iIJ0D27TmrY40EHwuhW0XX8du9UEAvUAdWsgbEU7NQD6re47PLUPFPVDoqtAZTE4PBOnB4PfEO4G3u5hjNbOQ6ulwGbTh70WqTfbzz2vaDtoexAFhgKjwXf7pRW/Fq53Ml8LofAmeFvwvxw32LXh3T64vBAwX8LzoS8KeAxAtWPI/RAo0PlH/LcPGqD4IaquBPTqdhQSvgd04+pklGf8Yxp3hIdVfU9F/N0IMvd+nwABtyYE0pdzx6cF/WZjszNsRvMxE7A1zVZt/7TzBzTGB6GXCKNnBFiXTqFAWXBwetVjcR1TAvCGVehiaAUgbZCneX7AZH0AYo0we0MQeB4ICuwVggmYBRwHdPlXcrLTb2VXAE3nB2XGB1cFCcHnJkFFbh/oVjhHfHcAQ0LQg2ondKUmO2VHOkIHCITGB08WCSNWe9MHCgfQdV9Hf3RweWVTas12hdNmOunBAq3ThX+QanogWpJQNYSlhtBgSmxIBEXzAIvXeABQAoECO1pjh32AbXsgXJRQAVZXOTuYBAeAUh9QiUsAAe2lAPNXhnIQiJlAcHiwap+hiUXQDQ7AAd5AXW8QTBFAAGfIBoYkipjAcnsgYGukBmXhVv+UpgYN8X08QYuoyAS2iAlPlwcySAwAlAABcE4XkV1vEAEfMAAdoAC/KIBucIyXsHd6cH2nyAYWNgcQIQ/gF35UhAJFuAW6JmiZ8HnKN3W/wEEMEBMvAQfVeAFr5YRNkH5f0I5XZDd70HdVVIxFYFSUlYZqoBVC0AH76IdLQJDsWADu+I69NweGhgwcFAEK2QZK5lxRiI5PEHVcAJABaWBzYIoFCQXf4A1CIFJBtgS2FQe9KA/3xY9O0GdZUHgVmQnVpwe/VxlsZHNJpV9L5QRtdY/iCBPnNAAXUIAQuQRheAUG15OYcH56YHCs5wubMQ8uiVYL0RBPcIZc15FowJD/b+AZ4DgFVfkJ+/eNLiiUUPASkSZbkAUIBNAAENCSUHmDpLZ8URAibekJF5gHUSePwhBjPpEEF1BfAhABzhhbd8kEnCgTntgGMpGU+kWMUrCWTMCTg+kJMJiV/acMinlYTDARzfVcTwCLshiS4ZcA14ARdhaVTDCVTvA6+mOVmnCEpZgCcamRajROjllQaAFfB5gEwWgRsEkGaOmQnNmZwdlpu0aRoABUe7ACA5YlT5AA6aAOKuZgfQEF1GiN2PgGHzmLazAaY4SYRIB31bmOlyAkeGgHLOOe4biebnWOY1CT8XCToBgFIlB+SdBv1SkB+AkJICRleoACZGQcBlkE//n4kGkAAUxJWU8ZnVKwjElQcrtGAVv5CCRAQBngamswRrwpl+upEAlgjW+Alht0WUGJBEUDO+RFCeVzPqrWPH8YoUPAYEKAW6FwHBxqBIX3ANNZCT1iAL+TbYq3GD4qBG82jKDgHjNaBF2ToI6gOZzzB1KipcwYpfUwTB3AkYowEN8Qk0rgHkU6BBi0CXHTTHewV7EnM2yAELWWnGjwAfzpBP7Zp0QwIhIgAqJQR1ADCCg6eGJ6FgEgbnBwD56op04wELQmqUh2ER9ZBfZUp5VAn5NYBxPAo4rKBgdglmsAAQfQDwlBoVEQFUpwqTGGBRmYCQv6qb73pNLAQUI6B//WYI8JUQVBIalIUCIqeQkjWkCEwAKAOapr8AERQJtvYBXxwAEMsKtT4KpKcWWzOgk5WqKFUGqcugwcpJnNOQaSNVJXUBbCOqxXVqyRsKRNWgj2lKIQKo58+QZqSgV4IRaytq0zaCxdeggpQKjt4EEdEADO2Jdn0HVlqaFXEEQ3mghxmgh9IxpiKq1bkY1mYHNKiZNYQDSPYKhyCgiXB6biKqZc1lpU2ga0BQAcIKa7IpGLcAJQdAglF671ugaZSQDWygZXUVvlOnMlqX6KAAPIogjzyhHjak4M8YlrcA+SJV3rqXUyewiFiQgD2xli6mPqkK9n0AAM8VYOmwX+qAj/b4kIFau1bkAACssJIVO1hHC1hnB5IdqjbNAAZ6iPcTChbRAyJIkIm5UIJRex2jCubsWqaCCt8YC4UugFOlkIySevIcACmCGmsXVQb3C5rji1X4CbwHeRgABsTcFBensSAKqzDqGeHssFnvkHuHgIy2Oy0aCrTclYXtcGDBG1TuuXXeC5gJCMhUC3YGG4Nhe0XwC2j2mqjfsFrcsHr1sIBke47iB+lcA0vtsHI5A3hhBElDsZi0oHlWmmY9sFzZsHX3gIojsX1CsG/RC1MJuA7QkI9TkIsUsX6xsGYrkQxps0Ozigf2C0iMCNo/u94hAHlygEAXC6vPsFbYoHcisI/wYnn5X7BmoRAF47Bhy7mZw7BleKB2c7CKGapAMsBXvJFjA5BS36mIwrBgybkOPrBQ3Masx0CNqJGJ7hYyyhVORUDS75EJrYwXUQuIVgaLI7ver0nSkBlmo1qXnZkAr8P7KZEbW5wGAQw3IQuYHgoDjbGagVEmPFkZIZxkdEUI8pixqsswRAri/8BYOaB0JMCGkjGaeZWkigWAcrxrLFBPoAE7U2xWeQl3v5DW27vGOwqXfwvKNDiHKsRuVIX6v5syJCSgjhAOtaBgc8Fe97Bv4KB8ArCGNzGZmRAN4QFQlwnGtRF29BEhfhx2agiqy4FfvLBbzjrnCAyIFAU0UcEP+gAVniycpDxbGxzAX+KbWrOwab3AbZC7sEu8i8CGO+TAbOCI2NesG2hwa03AbnSwiGDMoELAfjmJYResxqML+BALKcAUAF4RAI8cxlUI83t8ZhALFxAMCHEAIS7Bg+egFINQSQNo365cIbjAbmfF4zbAh/e84+CoJDoNBtIL4xugZwmwYfPAgU0L0IrQYMoWKK9cSJq7G2SQZlywYPfMvLys28+BJttcJloMYBnQYRbQZvTAj+OxwC5M7x0M1kCdDFPDSHtgZYHAiaVrfDu6jgMAocFNRrENODYHbDgcBRSkx1GQcQQF06HaBpgDpqYMuCEALSi89qoFjyUMll8J3/HWvVaIACPY0GnSwIIU3TPhoAEeCQzxoHryUALotiIJWtbvCgZ6DVgRDHTZ0YuFZMmeoGlvmaVuBjR6XXbTDTZpDMh7BXge3UuAbMb5DK/2kFZcUEsFrYaoABRDsG2VwInzzZANTI7+wGBAi2F0DNSqBYjPWrRwZjnq0GIbDFWEDOt8xrpt3NjMBarsXOg0TA/FYG9HwIbTzZgr0LypXH2/UGBkdXBb29fN3bvbBe7cVhbpAC96wFEz0IA23dvBC+wj3ccMACy/wFI73V9MrMRkHVt9vSF1QAufwESj0IoK3cQ8BBlakWu5sGqlrWH50Gj9sFPy0IFa3flL0Grqm6/z7L0QMu0NvpBfctCPGr4By0nCvLBhegvNrYBkjdBX4dCEDc1BtZjdfo0WYwZA0r322A1V2w1oJgT0J9GByE2oDKwlAIz2mgAWmtBSMOCEyt4AverE6p0pdgSAfHBZCNCFxN5EWeBk0sBw2QiavM42ng2Fgw2sEb2vptuByA5GUQtgJOxW1w0Lltq3tQ4BgupgzwnZdp2FaRxpk8B7edBccd2SXd5qoNtZlLAJC54RGuBsV9R9N9CKUN5cu9kN9JjdPIAPocAcH8bXMQ3Vfw3YNgxeKtBvcQ5qDEAEVla1hu292dT4duCMmt6IveBBCQieh6wk8w5VSel7Ju1m+A3v+AB7qA8ABd7dZzmdo67ElRDK1uQGvj5OGUiDz0TQUHzta4quib4RdBAQBKnL9LkJk77gYKYE7MOepqANhSUOGD8NJf3sUa8apWQRR4zNl6ea+GncaI7eJwoAETDgVBDgj5rer7be7nGEoR8Vix5QSXnImXzQEOANfIzn0puexRIOODsDj6vt8qpZoRwZpM4MqtOOlcgKePKdZCawcw/gT3/mF7Du3DefDSWsrvdcqczbEqbgbh5vEfXwc+HgVNjrbpre+hDOcO0ctOEM09IY1V6ttHsOQ9ZEdYY/QRv+po8M1766san2BEbwSJzgS6PQi/tvQSj2vDfuWGLelVPej/Z+7lSJDnTt7rm34G2J7aLNvNY3bn7XPqc0v2qg5AgOzu4vQWXr/TcqACBHoEmE4IbB7x9FgOF/DyY53tfB8Hlp4E6z0IBlffF70Gnjhf/40GCSHI3t4G9qwE4j4IWq71GT5OXhf1WjCT4KwHqW4EzW7hvK31UY4Gz7oSgs7pim/rc3DhRvD5grD6sM9BGLuK0YqGm98G4I4kFsMIvA77gSqmVd4BEjbImHB6LFDvQ+Dw4P3jzO9BMV9IU48EmtZXIw8Ix7/9bi4Poj70SGjRvqK9iZDvzL/1axABkcZeED79348ENT8EXA4EAOGQWDQekUnlsriSMKFR6ZRatV6x/1lkIKDFCgjCwMCrDVwAiUGnbOW24cfJAzQ8VeJ5K6gw0f8BAwUH3waRHBQCDiIODJciGIQ4yByNCiuxRJ4AYEYwK1VEPkdJS/UuRyEiBAQcGkyHwMQoSVFhmVBCABAWLG715up+h4mLAWxHCSCIHRw6OhhNkY2LHkoyNqjLWCi0vb8Ju0gTAj5eiTtYBSISsgje36mmv1VqesGxQlDw+fvNxD8lWLXu3DByH9plUcdKHsB+JWJ48Ecl10SLF5nME/RBwIEDAj5ghMIKXkOLJGLsE7mEgoaVL0VqDDRGyACHpcAMWEjLCqsBF8IkIcCF6Jib+DzIEAXzSIkHfphG5f8nE1CACAMGRFAwoJGpARAOYMXa9cqFABzWJTwytKjRiRYW0HggtYgIFXTxeqP6J8BCn78YRIqjM2iUvcQ2ZACQwiXeCQWE5ZU87HCeBPDgLbt1gScWAg7OEpxS+RZcBABYrMgrQfVk17dIvybCQEFmLAkcsHKgWUpsUyNgCHkMVeoDDLKRj/KNXKe6zpiWj6pwgsiKxlFZpEi+vVL01wyKCq51VNsdIhq0M52w4oFK7u+rkodfBELC+tLkF+tU5HFkkRgeWIG4+QhswzvXbJoFP3x48aUuFlaaQIX2CqwQjgPzgiCrrbJ6rrv8hsHmiIowwiAECga0UMUrMMSLAL//ImCjlBYDaRAJayyS8AEIV+wRCxrxOkA8WID8wwOJkLBrIhMp8M/HJ3sD0YgEPijnnAbAY6CglRoIC4ILZBzvGxIMICGJEnTpZ0IeoWwzyimaa0WI3HRygKkLSOIAjRmlNOXIJfTBp4QUmnTTUMNsaqswIzpooAEFwEgHDTzDFAmkAYby0JEi4zBtiVDAkaAANg8tNQmjFGUCUnIE6KKvPsERoANMf1pQm8SYAGEubQZNoQRTgT0V1iI4auTVY1qFiYMItBJgyE84bcNTJhijRtRNgs22CN8+4kCIYgH4KKSXGsAzGluNAS6K1Irp9Vdt4R0iNjwTCYCABASobdV4/5WI1ovppOAjxVJYeABbfuGNza8uaMv3WYwaqJKLhz+kxjwprLsFBAp8RRhhf2GC1Dl0h9lvCg26MaVgFQb2OFiQXxIAqHd4U25YQ2ycoj9SNg7hOJc/vnm7A7z9BWYrRKxCBFIdWblloF8WOjkGdiIZlpwpSs+R9XyG2uWjLb1qLKv9RNIKHA1B4QGWvf5aauQSoextPcg08wolBVmPwrbdbvOAegOgeNO58/gTCzQDwaBgAfkGGmyM4hRAU0Meh2LafH4uowQNVKCggBBWcK9xjyu3CALMaoaWcDhw1QJULCZAQQIKHghQAgyeHj3e0i9SBrbVy7j88F2nwIC1EP8KoEAFFJzU3Wve/VFFty1Vv0XdMlIQHYnNRUihgBRE0OBd58mHvh8FElmkaDFNyYC6Ntg1AgQUOv/ciczJz18M4CWT5ZjJw1EKC2zgYmUQGAAmYDz2PIACEkBB7vTnPPPxQwFA6YAD1mezUZDAAwtQTB4oQAHkKU98ETThFviXF6qxIgKpg04KpYCADBjAA6fRg+Lwd0IdbguGeIFAOdTCPkNUYAEbsNsOkfhCN3UgAORwYcUGYYETnMBBSbTi4PxGkgtksHqBIMEGFoCHK46Rcj2USgQ44IBMka0NCPCAATJgQzLOMT5tygkBJsFGL2RgAR44Ih0BmYcJ4mMAiMD/07iE2IbpbKCKgXTkhcwYFem1gnpKlBYBxfhITRooklLxHZFgyEEPbpKUnHySE8nBhSB2EQsypKEcSxlLFnVyJQFQQANexIoUnm6VGQEeEY0oS2H+iJYi4QoAXjQGAEJBelLzjhSpOExpuqGYkGuEhsK1TCbkJllCaYtbqPDFME6TnCbx0bI0IxAuyoMR3UQCW4qSoBi+MY7ltKdhqtk7nzRnUVSAgKyONZqb8dGP9zSoL6HEgIFAIgt9WYjQDuOCEzDyoBXtVz5FEg8tXAaPAuBALy8KBRdk0qIl5WEVPgkALAWukj0K6JtMGtMqxOaHkhsCneTUuEHKFJCxaQ4l/yQFAErpFKM8JSWqitLPIryIEsd66fOKalRNIpUoSiUCU8WQrKdCbadSHaNvsAoAcImLqF416xFoyhE1NgBf+hIASEkX1bPS0acLCUPDFCC4uM6Vr8eQa9D6OteuRi2wZx0ssA5b2PwltlSMVazuHGuoyD6Wb5Ntk2Upy9W/8guzme1bLDvrWcCCdrOiXWxpE4Za00JWtdkK7Wq19doVyRa2iG0tYWt7UNpaaLe5lextbetbg/a2QMQV7pOMO5/kHne2wDXVcpnLW+c2drrRdW11f2vdaUKXO9zVLny8m5zwfnc745WNecl7Xuy6Cb3pdU17JwNf9+ZFvvRd73yRe/9fKNUXv1HhL13+29+XBNi/+hWwdGVJ4ANfRMEwafCC/fFgU0CgSloyJ4TpKrSVWhhYVRMohnsqNJzaCViRwJcAlgBPLmDlmy128YthHGMZz5jGNbbxjXGcYx3vmMc99vGPgfxNFnPBqkQI6lCBRYCPSEnFNh5ykKFMlCdHOcpTpnKQrXzlH2dZyzzmsoyLLC+turNUDNAJWQRpYLSqec0TMS5xYeZUMpuKMHxh80kjfGc89wPOxRwrSEz1GUWwAq7/yLOb9UyENyd6f39oKwH2VSrcsEIBlYpDnxGd6UPzuZp41asVMb1pTmt6KoweXahHLepSq7qwGuWHq18dZmr/wBoftP6GrUGca13vmte99vWvgR1sYQ+b2MU29rGRfQRcFtoRFGZpEnh5C1xippIrtXQlUupsDq+FN6eDR0vbkFJrI4FKViLC6QJRbnMIATNW1faWmNjEkiZAMwTAk3M9bIRm3iKX6uhnA3KTGzQboqa0yPe5+0KLyMkaCwUXAsBb0ZEjxInECVAoigFBcSH45QgehngzGC7LjopDHc41MUOOwE3nTnuFqwRXpB3x0yGcHONFkHlNQPIOcGvh5i9/K6McBakwOLTmemjUo2RBElzTXBKAPiiWIMWBRW2VFEqesxjaiV20rLMvjagzJsLK7iW/06Y4d8AAPq2FsHYd/wBfPwLMUS6IffkEKO8cOwBWUSdml3IVB+gl1UdhZokTXRkAvfo4CI0skpw4K/7DdtmFIPhG9FscYT+AIlZx7XCXnfGreEfJhwCuWBT9D6I3C1rYQfnIn3njYNj6PW2JxlUCnhSE4SgBGkB0Xf7i9Wn4NgB+2LBkQH4IhJn2vdhN/KxWM+zBh5RK4ZGQbhUh7n+Yvs3BcPwg1nkVyFQ+OQWPKXZvPeSAEPRHfk4Ejm5974PIJVwZYG+JY4LCrcD9+RNPH7XiHgAK8Ijn/6D+1goA4g9PBk4I6IXIfG/x/iAB7UXQUI968O/n0CI0TM1QEoADxoXjSmHS8kXzlu8XWP8PCSgNtRbOAytt4uxKqCgt7bBg4QCgBEnwoRRv9/RgYTxwN6aEm1JQpfBk/pItCIVwCImwCI3wCJEwCZVwCZmwCZ3wCaEwCqVwCqmwCq3wCrEwC7VwC7mwC3tk2rQhLLwQttAPBD+h7HRiDFdLZNZnVjigEOyNK8BtKDrgAi4g99BOCCBgEg7gFehwEtiAahJBDWTFDjXjA8ai/dTwoNLhA1bhFdIBNJ5PUj5iTyxhHXIjAhxgFRJAIEBDE5HlKgjtI65CQ/IlNxQAANDi8tRoEc0KLTLQWdru59Lw3myJ9MQsDGyqLwiAI9jgI2oqDD5CFykhDQEgN1jQLMrPFe3KqQF8AlLsxBjTUCeKYguSjgx4kReRZShkQRvREOPSsAHSiBXMkBkNiiPe0CoEACxapQOejyMsyFs4YuqucRv/CSgUIAK2cR/z5V6kEcU00OoQyRxNKjfO4SP6UCfQB+NuUWaEKhUVrR61sWF0UBstkhVMEeeOYRXOhSDnyuIIQKFIzAgYyiOHbZIu4IkSwBJNsiVd8iVhMiZlciZpsiZt8iZxMid1cid5sid98ieBMiiFciiJsiiN8iiRMimVcimZsimd8imhUiiDAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Geometric mean anti-HHV-6 antibody titers (blue) and the proportion with HHV-6 DNA detected by polymerase chain reaction (PCR) in peripheral blood mononuclear cells (red) in 2427 infants and young children under the age of three years. Children with an acute febrile illness due to HHV-6 were excluded. HHV-6 DNA was detected in 10 percent of infants less than one month of age, which is consistent with perinatal transmission, and in 66 percent at one year. The rate of seroconversion was highest between 6 and 12 months of age; the high titers present in the first few months represent maternal antibodies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hall, CB, Long, CE, Schnabel, KC, et al, N Engl J Med 1994; 331:432.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27358=[""].join("\n");
var outline_f26_45_27358=null;
var title_f26_45_27359="Ab changes w SCIT";
var content_f26_45_27359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Changes in IgE and IgG resulting from subcutaneous allergen immunotherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 471px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Profile of a typical patient illustrating the dose regimens for immunotherapy and the IgE and IgG antibody responses. Plotted are the relationships between time expressed in days, individual and cumulative doses of RW pollen extract expressed in nanograms of antigen E (AgE), and serum levels of RW-IgE, RW-IgG, and total IgE. A) RW-IgE, RW IgG, total IgE data. LL, large local reaction.",
"    <br>",
"     B) Progressive cumulative dose (line) over respective single doses (bars) over time in days.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Creticos, PS, Van Metre, TE, Mardiney, MR, et al. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984; 73:94. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_45_27359=[""].join("\n");
var outline_f26_45_27359=null;
